2013 | November 3-5 Grand Hyatt Hotel New York City P4C Connect helps you find ADVANCE YOUR nontraditional allies—like leaders from nonprofit foundations, academic institutions, and R&D OBJECTIVES philanthropic organizations— who can help you advance THROUGH your R&D goals. REVIEW PROFILES OF OTHER P4C PARTICIPANTS.
P4C CONNECT! SCHEDULE ONE-ON-ONE AND/OR GROUP MEETINGS.
BUILD YOUR CUSTOMIZED P4C SCHEDULE—FROM PANELS TO PRESENTATIONS TO PARTNERING MEETINGS—AND SYNC IT WITH YOUR CALENDAR OF CHOICE. It also allows you to request free, private, 25-minute advice sessions with expert consultants on:
STRATEGIC PLANNING
COLLABORATION STRUCTURING
ATTRACTING CAPITAL
CLINICAL RESEARCH, REGULATORY, & REIMBURSEMENT STRATEGY Get the mobile P4C Connect app: P4C Connect is accessible DATA NETWORKING via your iPhone, iPad, or Android device. You can download it from the iTunes App Store, Google Play Store, or scan the All partnering meetings are held on QR codes here. the Conference Level.
iPHONE iPAD ANDROID TABLE OF CONTENTS
WELCOME LETTERS...... 2
HOTEL MAP...... 4
PROGRAM & ACTIVITIES...... 5
THERAPEUTIC AFFINITY & RESEARCH BUILDING BLOCKS ROUNDTABLES...... 33
PANELISTS...... 37
EXPERT CONSULTANTS...... 123
SPONSORS...... 141
TEAM...... 163
ACKNOWLEDGMENTS...... 167 WELCOME TO THE FIFTH PARTNERING FOR CURES CONFERENCE!
Partnering for Cures is a platform for big ideas, transformative programs, and tangible results brought forth by some of the most disruptive innovators. Each year, a kinetic energy permeates this meeting as participants are bound by a shared sense of urgency and a drive toward solutions. We measure the impact of this conference by the progress each of you can make—whether it’s finding vital new partners or garnering the latest intel on innovative programs or leaving with new vantage points to approach a problem. We’ve designed the program to do just that: • 16 dynamic panel discussions will tackle issues that are key to advancing medical progress. From big science to big data to big systems, the issues at hand are immense. With more than 80 panelists focused on collaborative solutions that are forward thinking and pragmatic, we know that you will leave with great optimism and practical strategies. • 30 innovators will be presenting their cross-sector programs—chosen after the most competitive application cycle to date. From novel financing models to adaptive clinical trial designs to data sharing initiatives, these programs provide all of us with a first-person account of the innovation that is underway. Take the time to review these programs—their transformative nature is sure to have ripple effects for years to come. • P4C Connect, our easy-to-use partnering system, is yours to utilize and leverage. You can schedule one-on-one meetings to advance your own research and development goals. This system allows participants—from innovators to investors, scientists to philanthropists, federal officials to advocates, to find each other and get things done. Through this system, you can also request private pro-bono consulting sessions with dozens of leading experts ready to give advice on topics including attracting capital, collaboration structuring, and regulatory and reimbursement strategy. • Time Equals Lives Talks—the latest addition to the program will feature remarkable speakers with incredible stories to tell about what drives them to continue to pave the path toward solutions— sometimes against many odds. Each 10-minute story will bring to life the compelling personal factors that come to play in the search for cures. • Numerous opportunities for productive collisions. Starting with breakfast roundtables focused on therapeutic affinity areas or research tools, networking opportunities throughout, and a late night gathering that will entertain and inspire you. • The P4C Lounge—be sure to stop by and check out the photo booth, add your thoughts to the “big picture,” and take advantage of areas for networking! We so appreciate your carving out time to join us. We know you will find these two days a productive and meaningful use of your time. Enjoy the meeting!
Sincerely,
Margaret Anderson Michael L. Klowden Executive Director CEO FasterCures Milken Institute T HE C ITY OF N EW Y ORK O FFICE OF THE M AYOR N EW Y ORK, NY 10007
November 3, 2013
Dear Friends:
It is a pleasure to welcome everyone to New York City as the Milken Institute’s FasterCures center convenes the fifth annual Partnering for Cures meeting.
New York really is the perfect place to host this event. Our city has a wealth of individual and institutional medical talent. We are also increasingly becoming a capital of the commercial life sciences, thanks in part to the ready access to venture capital that entrepreneurs have here. Earlier this fall, we celebrated the opening of the New York Genome Center, to which our Administration contributed $5 million in financing. These kinds of targeted investments are key to bringing new products and procedures to the market, and together – during this, the era of healthcare reform and innovation – we can expect Partnering for Cures to further advance the efforts of medical researchers from across the metropolitan area and beyond.
On behalf of our great city, I offer my best wishes for a productive meeting and continued success in your vitally important work.
Sincerely,
Michael R. Bloomberg Mayor FINDING YOUR WAY AROUND
Elevators
Registration
Empire V Empire Ballroom Empire I Breakout Breakout
Ballroom Level Majestic Partnering Shubert Help Desk Elevators Booth Partnering Booths 3 Imperial 2 Morosco 1 Wintergarden Plymouth Palace Broadway-Julliard-Uris Royale Alvin-Carnegie Networking Lounge
Conference Level 1. Ambassador 2. Orpheum 3.Gershwin
Elevators Regency Room
Park Ave. Entrance
Park Chrysler Avenue Room
Mezzanine Level
Elevators Front Desk
Concierge
4 Lobby Level 42nd St. entrance PROGRAM & ACTIVITIES
PROGRAM & ACTIVITIES NOVEMBER 3, 2013 SUNDAY PROGRAM & ACTIVITIES
6:00 PM - 8:00 PM EMPIRE BALLROOM FOYER Welcome Reception & Registration PARTNERING FOR CURES CURES FOR PARTNERING
NOVEMBER 4, 2013 MONDAY
7:00 AM - 7:00 PM EMPIRE BALLROOM FOYER Registration
7:00 AM - 8:00 AM EMPIRE BALLROOM Therapeutic Affinity & Research Building Blocks Breakfast Roundtables (For a list of roundtables and hosts, go to page 35)
8:00 AM - 9:00 AM EMPIRE BALLROOM Opening Plenary Big Science in the 21st Century SPEAKERS: The BRAIN (Brain Research through Advancing Innovative Francis Collins, Director, Neurotechnologies) effort initiated by the Obama Administration National Institutes of Health has captured imaginations as a national commitment to unlock Michel Goldman, Executive Director, the secrets of the human brain and find new ways to fight and treat Innovative Medicines Initiative neurological disease. Described by some as the next “big leap” since Richard Pops, Chairman and CEO, the Human Genome Project, completed more than a decade ago, Alkermes how does or should a “big science” project like this look different in 2013? Is this the right place to focus our scientific energies? What can Arati Prabhakar, Director, Defense be done to more quickly spin basic discoveries from such efforts out Advanced Research Projects Agency into therapies? Who should decide what the “grand challenges” Marc Tessier-Lavigne, President, to pursue are? And how does the rest of the scientific community The Rockefeller University get integrated with efforts like this – including citizen scientists? MODERATOR:
Margaret Anderson, Executive Director, FasterCures 7 8 PARTNERING FOR CURES PROGRAM & ACTIVITIES MONDAY 9:15 AM -10:109:15 AM AM -10:109:15 AM AM Partnering andExpertConsultations PM -12:00 9:15 AM BREAKOUT PANEL BREAKOUT PANEL health? What’shealth? to build needed and sustain efforts? these adoption care of practicesand evidence-based improve of rapid learning systems that are working the to speed as long as R&Dprocess. the Where are we examples seeing widespread to use improve patient outcomes, can which take approvalbetween of atreatment and its adoption into discoveries and research inhuman subjects, is “T2,” gap the “first the Beyond translation gap,”scientificbasic between Turning OutputsintoOutcomes The OtherTranslation Gap: should for look what inpartners, are pitfalls the to avoid? lessons about what are areas fertile for collaboration, what one goals andthe collaborators, the can we draw some common grow inimportance. widely depending on vary While they point of “consortium fatigue,” continue effortswill these to way. Even though it may to some seem that we’ve reached a that highlighted, can and be many lessons along learned the many such collaborations ongoing, many outcomes successful from government to patient groups. Andthere infact are that engage multiple stakeholders, from to academia, industry manySo challenges research inmedical require solutions Collaboration The ArtandScienceofMulti-Stakeholder
MODERATOR: Alpha-1 Foundation Centered Outcomes Research Institute MODERATOR: President and Medical Chief Officer, Merck Organization & CEO, Biotechnology Industry Heritage Medical Systems Multiple Myeloma Research Foundation Beth Meagher, Beth Rosenblatt, Michael Greenwood, C. James Freire, Maria Walter Capone, SPEAKERS: Cecilia Arradaza, Walsh, John Wagar,Mark Joe V. Selby, Peter Margolis, SPEAKERS: Communications &Policy, FasterCures Operations, Deloitte Consulting LLP Hospital Medical Center Excellence, Cincinnati Children’s Anderson Center for Health Systems and Director of Research, James M. Foundation for NIH the BOOTH/IMPERIAL/MOROSCO Executive Director, Patient- President and CEO, President, President, Director, Strategy & Chief OperatingChief Officer, Professor of Pediatrics EMPIRE BALLROOM I BALLROOM EMPIRE Director, Executive Vice President ALVIN
PROGRAM & ACTIVITIES PARTNERING FOR CURES 9
Chairman, MONDAY Founder, Orphan Orphan Founder,
EMPIRE BALLROOM I Deputy Executive Executive Deputy EMPIRE BALLROOM V CEO, American Heart American CEO, Head of Venture Investing, Investing, Venture of Head FasterCures Bill & Melinda Gates Foundation Gates Bill & Melinda Director, Carol Franc Buck Breast Breast Buck Franc Carol Director, Surgery of Professor and Center, Care California, of University Radiology, and Francisco San Disease Pathway Project Disease Pathway MODERATOR: Director, Director, Ronald G. Harrington, Bob More, George A. Weiss, Melissa Stevens, PRESENTER: Laura Esserman SPEAKERS: SPEAKERS: Nancy Brown, Association The Harrington Family Foundation; Foundation; Family Harrington The BioMotiv Chairman,
I-SPY is a paradigm-changing clinical trial process designed clinical trial process a paradigm-changing is I-SPY targeted of the evaluation for path accelerated an create to Drug and Food for cost the time and reduce and agents II trial Phase a standing 2 is I-SPY approval. Administration +/- new chemotherapy of the ability test to cancer, in breast in surgical therapy definitive to prior shrink to tumors agents will 2/3 high-risk disease, success stage with where women agent/ “graduate” survival.goalto is The lead improved to in a a high success likelihood of have that pairs biomarker Phaseis a III 2 patient-centered, trial. I-SPY confirmatory the drugfor the right finding accelerate model to replicable and faster do so to much time—and the right at patient right cost. less much for I-SPY 2 Trial Philanthropy: Philanthropy: Search for Cures for Impact in the Investing in the medical research a drought creates sequestration As are philanthropies venture and traditional pipeline, finance more (and more funding by gaps some plug to up stepping individuals and foundations For basic) medical research. they can learn and lessons what this new sector, to are that due project new for models of they in terms can teach what determine do you How evaluation? impact and diligence best practices for are What prioritize? to which research can how and portfolios, grant medical research evaluating dollars? your of the impact demonstrate you
INNOVATOR PRESENTATION INNOVATOR BREAKOUT PANEL BREAKOUT 10:15 AM - 10:4010:15 AM 9:15 AM - 10:10 AM AM9:15 - 10:10
10 PARTNERING FOR CURES PROGRAM & ACTIVITIES MONDAY 10:15 AM - 10:40 AM 10:15 -10:40 AM 10:15 AM - 10:40 AM 10:15 -10:40 AM INNOVATOR PRESENTATION INNOVATOR PRESENTATION of would them support individually. members to early-stage fund and research high-risk that none impressive financial leverage (20-fold),whichallows private are research to all fund pooled projects.gives This rise to an on acollaborative approach where sponsor the contributions private partnership. CQDM’s unique business is model based CQDM funds pre-competitive research conducted inpublic- productivity and accelerate development the of drugs. new innovative technologies that improve biopharmaceutical R&D and CanadianQuebec governments. Its mission is to fund GlaxoSmithKline, Boehringer, Lilly, and Novartis) and the pharmaceutical organizations (Merck, Pfizer, AstraZeneca, CQDM is anonprofit organization sponsored seven leading by CQDM research minds across globe. the arethey data and used, connect these to PPMbrightest the will contributes data their can determine has who access and how of data, health from molecularto environmental. Everyone who individual patients and patient communities–and types all creating embrace will healthy everyone–the and sick, the toneed better treat and The cure disease. platform PPM is to enable kindof the population research desperately we all build acommunitywill of people sharing data, health their People Powered Medicine movement (PPM) is asocial that People-Powered Medicine Harvard MedicalSchool/Wondros: Harvard Medical School Countway of Library Medicine, Biomedical Informatics & Executive Director, Center for D. Perakslis Eric PRESENTERS: President &CEO, CQDM Gosselin Diane PRESENTER: ofBoard Lybba Wondros, Founder &Chairman of the Founder Executive &Chief Officer of Jesse Dylan
EMPIRE BALLROOM V BALLROOM EMPIRE ALVIN PROGRAM & ACTIVITIES PARTNERING FOR CURES 11
MONDAY EMPIRE BALLROOM I EMPIRE BALLROOM V
Nancy Brown Association Heart American CEO, PRESENTER: Chowdhury Sohini Research President, Senior Vice Fox J. Michael The Partnerships, Foundation PRESENTERS: Jeffrey Olgin Professor, Investigator, Principal University Cardiology, Chief of and Francisco California, San of
Through MJFF’s PD Data Challenge, researchers sought to to sought researchers Challenge, PD Data MJFF’s Through through clinicians and patients benefit to the best way develop winning The collected data. passively these objective, of analysis the of 630 downloads than more entry following chosen was provided LIONsolver in 21 countries. teams from dataset could that approach” learning a “machine for concept of proof embedded in data progression and onset PD to clues unveil smartphones. collected on Michael J. Fox Foundation: Data Challenge Parkinson’s to is committed (MJFF) Foundation Fox J. Michael The about data contribute to patients for opportunities developing phones disease Mobile (PD). Parkinson’s the experience real of devices. monitoring of pervasive the most of forms some are through collected information Over MIT researchers 16 weeks, controls. seven healthy and patients PD nine from phones mobile Health eHeart Study Health eHeart decentralized a is paradigm-shifting Study Health eHeart The links to and sensors apps, mobile the internet, utilizing study real-time and collect to real-life medical records electronic heart disease. of treatment and prevention, risk, study to data of enrolling goalto is designed a be with scalable, study The diseases, will other to and transportable people, 1 million rapid for allows It data. of amount unprecedented an provide particular of types of randomization selection and substudy trials.is infrastructure also The ideally intervention to patients The paradigms. disease large-scale management study to set up and develop to also is a rich environment Study eHeart Health health technologies. mobile new and sensor validate rigorously
INNOVATOR PRESENTATION INNOVATOR INNOVATOR PRESENTATION INNOVATOR 10:45 AM - 11:10 AM 10:45 AM - 11:10 10:45 AM - 11:10 AM 10:45 AM - 11:10 12 PARTNERING FOR CURES PROGRAM & ACTIVITIES MONDAY 10:45 AM -11:10 AM 10:45 AM 11:15 -11:40 AM AM INNOVATOR PRESENTATION INNOVATOR PRESENTATION entrepreneurial philanthropy and alicensing inJapan. partner advisors, combined and experts, with financial the support of unique collaboration of management an experienced team, andto science both business. This approach includesthe Allegro’s success to date results from its innovative approach in both animalsand efficacy and initial human patients. progressed to from establishing discovery drug safety three years and at of cost, Allegrohas afraction industry degenerationmacular In and edema. macular diabetic only options for leading the causes of blindness: wet age-related effectively bringing to market new and improvedtreatment Allegro Ophthalmics has one quickly, goal: safely, and cost- Business ofDrugDevelopment Allegro’s InnovativeApproachtotheScience& A FasterWayForward: development and of delivery urgently TBvaccines. needed R&D has potential the to transform and accelerate the This first-of-its-kindmechanism for financing TBvaccine TB vaccine development efforts portfoliousing a approach. Vaccine Initiative to develop aviable business to advance case and Innovation and Tuberculosis the Advisory Services of European the Investment Bank’s Research, Development partnered with European the Commission under guidance the solutioneffective is prevention. Aeras, a nonprofit biotech, has complicate efforts to control epidemic,global thethe most people eachyear. As spreading drug-resistant forms of TB Contagious and airborne, 1.4million tuberculosis kills Business CaseforInvestmentinTuberculosis R&D Aeras:
Vice President, Affairs, External Aeras Kari Stoever PRESENTER: and B. Harry Helmsley Charitable Trust ProgramSenior Officer, Leona The M. Agiostratidou Gina Allegro Ophthalmics, LLC Co-Founder Technology &Chief Officer, Karageozian Vicken Allegro Ophthalmics, LLC OperatingChief Officer, D. Kirshbaum Marc PRESENTERS:
EMPIRE BALLROOM I BALLROOM EMPIRE
ALVIN PROGRAM & ACTIVITIES PARTNERING FOR CURES 13 ALVIN
MONDAY
EMPIRE BALLROOM V
Claudia Mitchell Director, Project Fund Research LGMD2I PRESENTER: Raymond A. Chavez and Research President, Vice Inc. Therapeutics, Xalud Development, PRESENTERS: Avey Linda Inc. Curious, & CEO, Co-Founder
Xalud Therapeutics, Inc. for treatment a novel is XT-101, lead product, Xalud’s pain, neuropathic diseases including neuro-inflammatory novel ALS, high clinical needs unmet requiring MS, and scalable manufacturing needed develop to We approaches. The funding studies. IND-enabling our complete to and pharma or capital venture these small was tasks by for required XT-101’s and unacceptable the was timeframe but standards, of Institute the National Fortunately, a concern. was novelty instituted (NINDS) had Stroke and Disorders Neurological theU44. as known mechanism, grant collaborative a unique recipients requiring focused was on translation, mechanism This an active partner remains NINDS The meet milestones. to development. during issues in resolving Xalud with Curious, Inc. exploring, gathering, for a new platform Inc., Curious, a patient-centric drive helping is personal data, sharing and two with has partnered company The movement. research their patient help LHP) to and (LGMD2I disease foundations that strategy in a new research participate communities They access. open will describe and sharing data promotes the program-related as well as partnership our the of goals their fuels efforts. that (PRI) investment
INNOVATOR PRESENTATION INNOVATOR INNOVATOR PRESENTATION INNOVATOR 11:15 AM AM - 11:40 11:15 11:15 AM AM - 11:40 11:15
14 PARTNERING FOR CURES PROGRAM & ACTIVITIES MONDAY 12:00 PM - 1:30 PM -1:30 PM 12:00 1:45 PM -2:10 PM 1:45 PM Partnering andExpertConsultations PM -6:00 PM 1:45 oneveryone planet. the treatments? These aren’t mere industry questions they affect – getting breakthroughs science basic translated into widely available solutions?meaningful What’s to accelerate needed process the of investors with expensive, the long-term work required to create lives? How can companies short-term balancethe demands of investment capital to support work that saves, improves, and extends industries and –more important –what done can be to attract bioscience innovation. What’s near-term the outlook for these moderates on apanel solutions focused –and on promise the of pharmaceutical industries. FasterCures Chairman Mike Milken We’re aware all of challenges the facing biotechnology the and Linking Financial,Human,andSocialReturns Investing inBioscience: Lunch Plenary INNOVATOR PRESENTATION research and infrastructure initiate faster and trials at alower cost. developers to quickly navigate and evaluate clinical pediatric with ViS’ online feasibility and analytics platform, allow drug participate at no cost. The resultingpatient demographics, together researcha pediatric network that allows research institutions to acrossexperience, 84 countries. Together, ViS &BIO are building companies, has mapped more than 3,000institutions with pediatric with Biotechnology the Industry Organization (BIO) and its member research sites for research. pediatric ViS Research, inpartnership is borne by children, but it remains difficultexperienced to find including schizophrenia, depression, and malaria, HIV/AIDS, Nearly 60percent burden of disease the for high-priority conditions, ViS &BIOCollaboration Empowering PediatricResearch:
Institute; Founder, FasterCures SPEAKERS: Founder &CEO, ViS Research Thiers Fabio Industry Organization President &CEO, Biotechnology Greenwood C. James PRESENTERS: Michael Milken, Kaul, Rajiv Hugin, Robert Partner, Lion’s Head Partners Global Egerton-Warburton, Christopher Celgene MODERATOR: Fidelity Investments and Advisor Biotechnology Fund, Biotechnology PortfolioSelect BOOTH/IMPERIAL/MOROSCO Portfolio Manager,
CEO and Chairman, EMPIRE BALLROOM I BALLROOM EMPIRE Chairman, Milken EMPIRE BALLROOM PROGRAM & ACTIVITIES PARTNERING FOR CURES 15 ALVIN
MONDAY
EMPIRE BALLROOM V
Rosemarie Truman for The Center & CEO, Founder Inc. Innovation, Advancing Roman Yelensky Roman Clinical Analysis, Genomic Director, Inc. Medicine, Foundation PRESENTERS: Marc Hurlbert Director, Executive Crusade Cancer Breast Avon Thomas StackhouseM. Transfer Technology Director, Associate Institute Cancer National Center, PRESENTERS: PRESENTERS: Jeff Allen of Friends Director, Executive Research Cancer
The Avon Foundation, the National Cancer Institute, and and the Institute, Cancer National the Foundation, Avon The a create to partnered have Innovation Advancing for Center challenge The Start-up Challenge. Cancer Breast of a kind” “first the National from (nine inventions cancer breast features grantee) Foundation Avon an from one and Institute Cancer public to important are and viability commercial have that the stimulate to is primarychallenge of health.goal The the these based inventions. businesses upon start-up of creation National Cancer Institute/Avon Breast Cancer National Cancer Institute/Avon Crusade/The Center for Advancing Innovation: Breast Cancer Startup Challenge This revolutionary trial will streamline the drug-development trial drug-development revolutionary willthe streamline This to together companies pharmaceutical bringing by process clinical trials experimental drugs in late-stage multiple test with companies matching By protocol.’ ‘master a single under the to relevant genetically most are whose tumors the patients will improve this protocol trying they are develop, to therapies reduce and market, to speed new treatments rates, success to slated is project The agents. individual developing for costs to adapted easily be could and expanded and year next launch cancers. other Friends of Cancer Research: Cancer Research: Friends of Trial Master Protocol Lung Cancer of Cancer Friends by spearheadedis protocol’ ‘master This Institute, Cancer the National with in collaboration Research the for the Foundation Drug Administration, the and Food Medicine. Foundation and Health, of Institutes National
INNOVATOR PRESENTATION INNOVATOR INNOVATOR PRESENTATION INNOVATOR 1:45 PM - 2:10 PM1:45 PM - 2:10 1:45 PM - 2:10 PM1:45 PM - 2:10 16 PARTNERING FOR CURES PROGRAM & ACTIVITIES MONDAY 2:15 PM - 2:40 PM 2:15 -2:40 PM 2:15 PM - 2:40 PM 2:15 -2:40 PM INNOVATOR PRESENTATION INNOVATOR PRESENTATION criteria inmore disabled populations. a second-phase project is planned to validate established the thefinalizingBased first-phaseon analyses. project results, conference, and stakeholder feedback was incorporated into composition. The findings were presented ata consensus operational definitions performance,of strength, body and to evaluate criteria for sarcopenia on diagnosis, shared based cross-sectional and prospective data from longitudinal studies government, pharmaceutical, and nonprofit utilized experts clinicians, regulators, and insurers. health The team’s academic, and outcome measures for condition, this acceptable to sarcopenia definition by establishing clear diagnostic criteria The Sarcopenia Project aims to create the firstevidence-based Biomarkers ConsortiumSarcopeniaInitiative Foundation fortheNIH: its business and model; unique collaborative partnerships. projects getting ready for INDand one stage clinical project; record development; indrug operational progress, with two novel is differentiated by aligned teamwith its an unparalleled track key stakeholders facilitating translational R&D. The company forging an ecosystem of and as academic partners industry unique connectivity, skills, and capital markets sophistication packages for pharma/biotech the industry. The company has opportunities from university laboratories into clinical-ready development and value creation, on with afocus translating utilizing an innovative technology/business for model drug new PharmaBessor and Brightwaters Capital are joining forces and Building ValueUniquelyTranslating UniversityAssets Bessor/Brightwaters Pharma:
Bessor/Brightwaters Pharma OperatingChief Officer Chairman,and Berkowitz A. Barry PRESENTERS: Foundation for NIH the The BiomarkersConsortium, Scientific Senior Program Manager, T. Vassileva Maria PRESENTER: Pharma Bessor/BrightwatersCo-Chairman, Boystak A. Joseph EMPIRE BALLROOM V BALLROOM EMPIRE EMPIRE BALLROOM I BALLROOM EMPIRE PROGRAM & ACTIVITIES PARTNERING FOR CURES 17 ALVIN
MONDAY EMPIRE BALLROOM I
Immunophotonics, Inc. Immunophotonics, , PRESENTER: PRESENTER: Charles Magness Inc. Kineta, & CEO, President PRESENTER: Tomas Hode CEO
Kineta, Inc. cofounders for company biotechnology the third is Kineta 2008 launch, its Since Magness. Charles and Iadonato Shawn vitalhave been efficiency to capital and collaboration, innovation, goal of its and research translational to approach the company’s pipeline high-caliber novel deals. Kineta’s clinical licensing early viraland diseases autoimmune targeting programs five includes been raised,have dollars million Fifty-two pain. non-narcotic and Institutes the National with contracts and grants from half derived facilitate structure flexible and collaboration Academic Health. of mission and offices, family Foundations, partnerships. creative the double-bottom to responded enthusiastically have investors major drugs for advancing investment – a great potential line its examine partners to potential welcomes needs. Kineta patient diseases autoimmune targeting assets, ShK-186 advanced most candidate. acting antiviral a broadly rOAS, and an in situ autologous cancer vaccine that is practical, cost-effective, is that vaccine cancer autologous situ in an these significant Given reactions. minimal adverse with comes and partner international to with been able they have advantages, end-stage to inCVAX of access early provide to collaborators results The options. treatment limited with patients cancer this Following be highly effective. may inCVAX that indicate to expand WIN) (I CAN theysuccess, started a nonprofit this of the the development Early accelerate Program, Access the most. who need it patients further and help therapy, promising Immunophotonics: Immunophotonics: Nontoxic, Practical, the World, Providing Changing Globally to Cancer Patients Cost-Effective Treatments the world. changing to committed is Immunophotonics inCVAX, developing company a biotech is Immunophotonics
INNOVATOR PRESENTATION INNOVATOR INNOVATOR PRESENTATION INNOVATOR 2:45 PM PM - 3:10 2:15 PM - 2:402:15 PM 18 PARTNERING FOR CURES PROGRAM & ACTIVITIES MONDAY 2:45 PM -3:10 PM PM 2:45 2:45 PM -3:10 PM PM 2:45 INNOVATOR PRESENTATION INNOVATOR PRESENTATION To date, more than 35 collaborations have facilitated. been institutions—22 of are which located indeveloping world countries. and24 academic, 22nonprofit or government research 70 members, including 11private organizations, industry WIPO Re:Search membership has expanded to more than with and academic nonprofit researchers. Since its inception, assets and resources, such as compound libraries and expertise, Hub, BVGH creates partnerships by connecting private industry’s tropical and malaria, tuberculosis. diseases, As Partnership the development vaccines, of and drugs, new diagnostics for neglected consortium. The aim the consortiumof is to acceleratethe pharmaceuticalglobal companies formed WIPORe:Search the (WIPO), BIO Ventures for Health Global (BVGH) and eight In partnership with World the Intellectual Property Organization Global HealthEndeavors A BridgebetweenPrivateIndustryand BIO VenturesforGlobalHealth: adaptable for by organizations. use other trial clinical for autoimmune, organ transplantation, and allergy, and is immune tolerance therapies and biomarker development The TrialShare is integralmodel to ITN’s mission of accelerating interactive formats encourage exploration of data and analyses. access to participant-level data and analysis Intuitive, code. Medicine publication where TrialShare provide links public as recently demonstrated inaNew England Journal of investigators to confirm and extend upon ITN’s findings community. The applicationallows internal and external collaboration among diverse stakeholders research inthe revolutionizes transparency trial clinical by supporting The Immune Tolerance Network (ITN) TrialShare system TrialShare ClinicalTrials ResearchPortal Immune Tolerance Network:
Immune Tolerance Network Director,Senior Bioinformatics, Asare Adam PRESENTER: President, BIO Ventures for Health Global Dent Jennifer PRESENTER:
EMPIRE BALLROOM V BALLROOM EMPIRE ALVIN PROGRAM & ACTIVITIES PARTNERING FOR CURES 19
MONDAY EMPIRE BALLROOM I EMPIRE BALLROOM V
Kenneth M. Farber Research Lupus for Alliance President, PRESENTERS: Charles Hugh-Jones Sciences Life Consortium, Member, Cancer on CEO Roundtable Beetsch Joel Sciences Life Consortium, Member, Cancer on CEO Roundtable PRESENTERS: PRESENTERS: Anthony J.Coyle for Centers Chief Scientific Officer, Pfizer Innovation, Therapeutic
of the CEO Roundtable on Cancer’s Life Sciences Life Consortium, Cancer’s on the CEO Roundtable of companies, allows that easy-to-use database an provides access, share, responsibly to researchers and institutions, III clinical Phase cancer historical of arms control analyze and initiative This oncology research. trial sets accelerate to data community in cancer the of allstakeholders the efforts engages solutions into data” “big transforming science by advance to the cancer enabling By the world. around patients cancer for the initiative data, historical of the value into tap to community duplication, reduced research, efficient more lead faster, to may transparency. greater and The Project Data Sphere initiative, an independent initiative initiative independent an initiative, Sphere Data Project The Project Data Sphere Initiative Pfizer’s Centers for Therapeutic Innovation/Alliance Therapeutic Innovation/Alliance Centers for Pfizer’s Research for Lupus andthe (CTI) Innovation Therapeutic for Centers Pfizer’s a partnership (ALR) announced Research Lupus for Alliance for new therapies discovering at 2012 aimed in November this first-of-its-kind part of As lupus. with living patients novel co-funding CTI are ALR and in lupus, collaboration academic leading by driven projects research translational among – partnership This three-way (AMC). medical centers structured a partners – provides AMC CTI, the ALR, our and program. clinical a ideas into scientific translating for pathway
INNOVATOR PRESENTATION INNOVATOR INNOVATOR PRESENTATION INNOVATOR 3:15 PM - 3:403:15 PM 3:15 PM - 3:403:15 PM 20 PARTNERING FOR CURES PROGRAM & ACTIVITIES MONDAY 3:15 PM - 3:40 PM 3:15 -3:40 PM 3:45 PM - 4:40 PM -4:40 PM 3:45 BREAKOUT PANEL INNOVATOR PRESENTATION need toneed accomplish kindof this systems change? and what mechanisms and other resources agency the does a recalibration of benefit riskand by FDA like look in practice, Avandia due to concerns about cardiovascular risk. What does of restrictions the FDA hadon imposed diabetes the drug year,Earlier this panel areview recommended removing some prioritiestheir are and they to tradeoffs the willing accept. allowswhich agency to the formally consult with patients about Patient-Focuseda new Development Drug initiative at FDA, products. In latest 2012,the reauthorization of PDUFA created more risk than FDA the has historically tolerated innew orwith deadly debilitating are diseases often willing to accept Patient groups have saying been for years that people living Recalibrating theBenefit-RiskEquation FDA: and commercialization, and CHS’s expertise. clinical community’s ENM’s needs, inproduct development expertise of eachorganization -COPDF’s understanding deep of their the inventor. partnership’sThe success rests the on strengths and by licensed ENMand royalties are splitdeveloped with with inputexperts from COPDF.best Theideas are then submitted and by reviewed product development and medical ENM’s Through proprietary, confidential ideas portal, are Search” to find new product ideas relatedCOPD. to (COPD).partnership The initial on an focused “Innovation individuals with chronic pulmonary obstructive disease System (CHS),to find innovations to improvethe lives of healthcare innovation and portal, Carolinas HealthCare Nation incubator Medical device (ENM),amedical and COPDThe Foundation (COPDF)partneredwithEdison COPD InnovationSearch COPD Foundation: MODERATOR: MoffittSciences, Center Cancer Member,Senior Division of Population Personalized Medicine Institute, Director, TPGBiotech and Company and Scholar, Neurosciences, Lilly Eli Biomedicines; Distinguished Lilly COPD Foundation Executive Director, Kephart Craig PRESENTERS: Kate Rawson, Kate Howard McLeod, Hempel, Hugh Geoff Duyk, Conley, Robert SPEAKERS: Carolinas HealthCare System Edison National Medical, Vice President of Innovation, Wright Jean Advocate, The Addi Cassiand Fund Therapeutics; Director and Patient Partner and Managing
Senior Editor, Senior RPMReport
Regulatory Leader, Regulatory Co-Founder, Solution EMPIRE BALLROOM I BALLROOM EMPIRE
Medical Director, ALVIN PROGRAM & ACTIVITIES PARTNERING FOR CURES 21 ALVIN Institute for Vice President, President, Vice Deputy Director, Director, Deputy President, President, Senior Vice President President SeniorVice MONDAY President, President, EMPIRE BALLROOM V Executive Vice Vice Executive Founder, Avicenna LLC Avicenna Founder, Director, National National Director, Executive Director, Director, Executive Director, Technology Licensing Technology Director, Licensing and Entrepreneurship, Office Office of Entrepreneurship, and Licensing Institutes National Transfer, Technology of Health & General Counsel, Worldwide Research Research & General Worldwide Counsel, Pfizer & Development, Life Sciences Initiatives, Xconomy SciencesLife Initiatives, Sage Bionetworks Sage Institute for Neurological Disorders Disorders Neurological for Institute NIH Stroke, and MODERATOR: Chordoma Foundation Chordoma MODERATOR: Lita Nelsen, Lita Sommer, Josh Robert Cook-Deegan, William Chin, Stephen Friend, Story Landis, Luke Timmerman, SPEAKERS: David Clifford, Steven M. Ferguson, Justin McCarthy, SPEAKERS: SPEAKERS: Blumenstein,Robi Genome Sciences & Policy and Sanford Sanford and Sciences & Policy Genome Duke University; Policy, Public School of Senior Fellow FasterCures President, Science and Regulatory Science and President, Research Pharmaceutical Affairs, America of Manufacturers and CHDI Management CHDI Office, Massachusetts Institute of Technology of Institute Massachusetts Office,
Reducing Drag: New Approaches to IP Negotiation Licensing and Technology fun pulling as much as about are negotiations IP Protracted ofthese inefficiencies teeth. Recognizing and the drag developing are organizations and individuals, transactions, IP transferring and negotiating, valuing, to new approaches into discoveries in translating unneeded delay reduce that drugs, new devices, services. vaccines, or diagnostics this In who are IP innovators leading will from hear you session developing by ease to transactions new mechanisms using early- revaluing time, negotiating reducing collaborations, altogether. property intellectual avoiding or IP, stage will address topics such as sharing of negatives results, clinical results, negatives of sharing as such topics will address and publishing, academic incentives, trial transparency, goodoutcomes of specific examples What reproducibility. openness incentivizing of models and results negative from culture” “innovation an create we can seen? we How have sciences? in academic life Learning to Love Failure Learning in science pays Everyone makeover. needs a brand “Failure” plenty occur can without servicelip progress no the fact to that negative for rewarded is one no but the way, along failures of panel This others. benefit them to share to incentivized or results
BREAKOUT PANEL BREAKOUT BREAKOUT PANEL BREAKOUT 3:45 PM4:40 - PM 3:45 PM - 4:40PM 22 PARTNERING FOR CURES PROGRAM & ACTIVITIES MONDAY 4:45 PM - 6:00 PM -6:00 PM 4:45 Partnering forCuresLateNight PM -10:00 PM 9:00 Networking Reception Cap off thefirst day of Partnering Latefor Cures with a Night gathering will entertain that andinspire you. » » » » » » WADE PRES SCIENCE GENIUS RAP ADAM RUBEN frequent concerts solo intheaters around country. the Movin’the Out Band and Billy the Joel band, varietyof leaving he sings styles eclectic the and plays to his is now returning to his roots “city with anew band” country Shotgun Wedding, called with members of preeminent pianist, boogie revered for his rollicking performances and stunning abilities. technical He concerts with Movin’ the Out Band™. Prior to Movin’ Out, Wade was well known on west the coast as the year from run May of December 2005,and 2002till starred national inthe tours 2008.He till does still Wade played “Piano the Man” role inBilly Joel and Twyla Tharp’s Broadway hit Movin’Out forthree-the natural reproduction, selection, digestion, solar the system, and a“burner named Bunsen.” stage the take Christoper with Emdin rappers will spitting rhymes about DNA, mitochondria, big the bang, of urban youth culture and it uses to spur greater interest education. inscience Program founder Prof. to teach science. Aprogram of Columbia University’s Teacher’s Genius power the harvests College, Science andLearning Engagement competition inScience) showcase will how hip-hop an can be effective means Thewinning teamsGeniusScience the of B.A.T.T.L.E.S. (Bring Attention to Transforming Teaching, guideto lowa satirical the points and, well, lower points of post-baccalaureate education. and comedy clubs. He is author the of Surviving Your Stupid, Stupid Decision to to Go Grad School, colleges, and private venues across country, the including at some of best-known the storytelling shows W riter, comedian, storyteller, and molecularbiologist. For over he adecade, has at performed clubs, TON
PERS
EMPIRE BALLROOM FOYER BALLROOM EMPIRE EMPIRE BALLROOM V BALLROOM EMPIRE
PROGRAM & ACTIVITIES PARTNERING FOR CURES 23 EMPIRE BALLROOM EMPIRE BALLROOM EMPIRE Co-Founder and and Co-Founder Assistant Professor, Professor, Assistant TUESDAY Partner, Partner, Deputy Director, Director, Deputy Co-Founder and CEO, CEO, and Co-Founder EMPIRE BALLROOM FOYER BOOTH/IMPERIAL/MOROSCO CEO, uBiome CEO, The Longevity Fund The Longevity SPEAKERS: SPEAKERS: Laura Deming, Geoffrey Ling, Jessica Richman, Halle Tecco, Adrien Treuille, Computer Science and Robotics, Science and Computer University Carnegie Mellon Defense Sciences Defense Office, Defense Agency Projects Research Advanced Rock Health Rock NOVEMBER 5, 2013 NOVEMBER Partnering & Expert Consultations 9:15 AM9:15 - 12:40 PM To mark Partnering for Cures’ 5th anniversary, this session will this session 5th anniversary, Cures’ for Partnering mark To of bleeding on edge the living are who individuals five feature the new about these paradigm-busters from Hear medical research. they that spearheading they are approaches and concepts, science, and system our R&D efficacythe impact of significantly could hope patients. to innovation the speed deliver which we with Plenary Five People Changing the Face of Bioscience 8:00 AM - 9:00 AM Therapeutic Affinity & Research Building Blocks Breakfast Roundtables & Research Building Therapeutic Affinity 36) page to go hosts, and roundtables of a list (For 7:00 AM - 8:00 AM Registration 7:00 AM - 1:00 PM 24 PARTNERING FOR CURES PROGRAM & ACTIVITIES TUESDAY 9:15 AM -10:109:15 AM AM 9:15 AM -10:109:15 AM AM BREAKOUT PANEL BREAKOUT PANEL chronic conditions? losing on focus and new better treatments for more common status aguarantee of reimbursement by payers? we Do risk with rare but diseases, how longlast? focus Is this will orphan “geneticallycancers”). defined This is greatnews for patients are embracing line this of (pursuing, thinking for example, considered could be cases “rare,” and clearly companies common redefined to be as thatsubtypes diseases in many can command prices. Personalized high medicine is causing Industry and investors that products see new for rare diseases Hot, butforHowLong? Rare Diseases: become more important? universities? What change will as other sources of financing businessthe to model demands support new these on all to education their and care missions. delivery What is Many are re-evaluating research their missions in relation for from activities these foundations and from industry. most are scrambling to find sustainablesources of support and outcomes research. As resources federal are declining, research and proof-of-concept way the all to regulatory science research and development continuum –from translational for to them play and new more significant along roles all the Academic research institutions are demands seeing increasing The NewValuePropositionforAcademicScience Nature Medicine Nature Medicine MODERATOR: President, Health Global Group; President, UnitedHealth Medical School Department ofGenetics,Harvard Translational Sciences National CenterforAdvancing Christopher Austin, SPEAKERS: BVF PartnersL.P. Matthew Herper, Simon Stevens, Matthew Perry, Raju Kucherlapati, Sharon Hesterlee, Collins, Mike SPEAKERS: Roxanne Khamsi, Jack Tillman, Pearl Huang, Louis J.DeGennaro, Forbes Magazine Dystrophy for Research,ParentProjectMuscular MODERATOR: Innovations,Emory University Emory Clinical Operations,Clinical Alexion Pharmaceuticals Development, GlaxoSmithKline in Academia,AlternativeDiscoveryand Global HeadofDiscoveryPartnerships Leukemia andLymphomaSociety President andChiefMissionOfficer, Executive Director, Vice President, Vice President for Global Executive Vice ExecutiveVice PortfolioManager, EMPIRE BALLROOM V BALLROOM EMPIRE EMPIRE BALLROOM I BALLROOM EMPIRE SeniorEditor, Chief News Editor, Chief NewsEditor, Vice President Professor, Director, Executive Vice
PROGRAM & ACTIVITIES PARTNERING FOR CURES 25 ALVIN
Director, National Director, National Senior Fellow, EMPIRE BALLROOM I
TUESDAY Chief Scientific Officer Chief Scientific Officer Chief Science Officer, Chief Science Officer, Director, California NanoSystems Institute MODERATOR: and Medical Director, Genomind and Medical Director, Jay Lombard, Paul Weiss, Kathi E. Hanna, PRESENTERS: GalskyMatthew Medicine, Professor Associate Oncology, Medical and Hematology Urology, Professor Assistant Hospital Sinai Mount Jonathan Simons W. H. Koch David CEO, and President Foundation Cancer Prostate Chair, SPEAKERS: SPEAKERS: Thomas R. Insel, Autism Speaks Institute of Mental Health, NIH Institute of Mental Health, FasterCures Robert Ring, dsourcing to gather input from the scientific from input gather to dsourcing ting a pilot clinical trial exploring metformin clinical metformin trial a pilot ting exploring Conduc “in a single person” will involve that cancer in prostate conducted visits study of the remainder with visit, study secure video through conferencing. remotely Using crow Using a clinical the design of regarding community patient and cancer prostate with in patients metformin trial exploring
2. 1.
Prostate Cancer Foundation to patients “bringing model of the current transform to aim We have We clinical trials patients.” “bringing to to clinical trials” approaches novel two of the feasibility establish to a pilot initiated model: the current transform to will help that Mental Health: Mental Health: at a Crossroads and Development Research ofthe ofchallenges allthe is a health field crucible mental The an and system, development and medical research broader So many policy the moment. focus at public intense of area these about to answered be remain questions basic scientific clinicalof challenges The conditions. neurological other and investors Industryand magnifieda thousandfold. are research are How in this area. particularly become averse risk have new promising surviving? in thisWhat field companies in being deployed are approaches development and research there Are changers? game be might health field that the mental of R&D? fields other for here lessons
INNOVATOR PRESENTATION INNOVATOR BREAKOUT PANEL BREAKOUT 10:15 AM - 10:4010:15 AM 9:15 AM - 10:10 AM AM9:15 - 10:10 26 PARTNERING FOR CURES PROGRAM & ACTIVITIES TUESDAY 10:15 AM - 10:40 AM 10:15 -10:40 AM 10:15 AM - 10:40 AM 10:15 -10:40 AM INNOVATOR PRESENTATION INNOVATOR PRESENTATION organizations to seeking catalyze cross-sector interactions. research projects. This approach shouldbe of interest to other model, and MRA Pfizer are supporting innovative melanoma melanoma. Through leveraged fundingthis highly successful breast cancer and, inpreclinical studies, suggests arole in Administration Breakthrough Therapy designation in potential of that adrug recently received Food and Drug opportunity Partnership Award to evaluate therapeutic the on program this and in2013,MRA Pfizer offered special a pharmaceutical, biotech, or companies. device Expanding Industry Partnership Award is anovel grant mechanism with Emphasizing cross-sector collaborations, MRA’s Academic- research worldwide to accelerate progress toward acure. The MelanomaResearch Alliance (MRA) supports innovative Academic-Industry Partnership Melanoma ResearchAlliance: that benefitfuture will generations peopleof with Parkinson’s. offree charge. We thatcreate believe will this alasting legacy available to researchers studying Parkinson’s over all world, the data, and samples blood study made inthe be collected will a patient cohort of more than 3,000subjects. The information, as it develops ingreater than detail everbefore, Parkinson’s across tocure find a forthe condition. UK researchers studywill and we that believe for is this critical us to achieve our aim biomarkers. At present there is no biomarker for Parkinson’s, five-year project aims up to searchspeed our forcure a by finding study of people with Parkinson’s. This ambitious, multi-site, Tracking Parkinson’s world’s the be will largest everin-depth Tracking Parkinson’s (PRoBaND) Parkinson’s UK: Parkinson’s UK Director of Research &Innovation, Breen Kieran PRESENTERS: Research Alliance President &CEO, Melanoma Wendy Selig K.D. Medical Director, Oncology, Pfizer Perkins Julia PRESENTERS: CEO, Parkinson’s UK Ford Steve
EMPIRE BALLROOM V BALLROOM EMPIRE
ALVIN PROGRAM & ACTIVITIES PARTNERING FOR CURES 27 EMPIRE BALLROOM I TUESDAY EMPIRE BALLROOM V
PRESENTERS: PRESENTERS: Alex Sherman Development Strategic Director, Clinical Neurological Systems, and Massachusetts Institute, Research General Hospital Melanie Leitner Prize4Life Chief Scientific Officer, PRESENTER: PRESENTER: Rachel Lane Affairs, Scientific Director, Assistant Drug Discovery Foundation Alzheimer’s
Neurological Clinical Research Institute/Prize4Life: Neurological Clinical Research Institute/Prize4Life: Trials Pooled Resource Open-Access ALS Clinical Platform (PRO-ACT) ALS Clinical Open-Access Resource Pooled award-winning An LLC Prize4Life, of project a joint platform, (PRO-ACT) Trials Massachusetts at Clinical Institute Research Neurological and model among serve may a collaboration as General Hospital, recognizedprojectwas The nonprofits. and academia, pharma, in Best Practices Award World 2013 Bio-IT the of winner as has platform PRO-ACT health IT category. the clinical and from subject-records de-identified 8,600 than more amassed a single, academic clinical trials and into 18 pharmaceutical clinicians, companies, Pharmaceutical dataset. harmonized and researchers from 30 countries are actively exploring PRO- exploring actively are 30 countries from researchers and clinical trials develop streamline and to seeking ways ACT, disease. Gehrig’s ALS, a.k.a. Lou for treatments better Alzheimer’s Drug Discovery Foundation ACCESS: Foundation Drug Discovery Alzheimer’s by the use of CROs to optimize A novel resource companies academia and early-stage (CROs) organizations research contract of use effective The by academia and early-stage companies can result in a shorter in a shorter result can companies early-stage academia and by partnering, clinical development, to path streamlined more and CROs, the use of optimize To securingand investment. the Alzheimer’s Drug Discovery Foundation (ADDF) developed (ADDF) Drug Discovery Foundation the Alzheimer’s on guidance strategic provide to program ACCESS the ADDF ACCESS ADDF a CRO. managing selecting of and the process expertise with CROs in of marketplace online an includes diseases a nervous system and central drug discovery for is ADDF resources. experts educational of and virtual network to expand funders nonprofit of a consortium building currently this resource. of the utility
INNOVATOR PRESENTATION INNOVATOR INNOVATOR PRESENTATION INNOVATOR 10:45 AM - 11:10 AM 10:45 AM - 11:10 10:45 AM - 11:10 AM 10:45 AM - 11:10 28 PARTNERING FOR CURES PROGRAM & ACTIVITIES TUESDAY 10:45 AM -11:10 AM 10:45 AM 11:15 -11:40 AM AM INNOVATOR PRESENTATION INNOVATOR PRESENTATION as well as LLS’s Therapy Acceleration Program™. grant academic focused program “Quest called for Cures” partner. The four-year collaborationfunds an innovation- In 2012,Celgene Corporation October first the became TLCP protected for negotiation period of intellectual property rights. opportunity to excellent, fund and science original maintain a high-quality research providing while an partner industry the It LLSmission the preserves and processes for identifying foundationsfocused and major pharmaceutical companies. to guideproductive research partnerships disease- between philanthropy, provides an innovative contractual framework Candidates Program™” (TLCP), anovel approach to venture Leukemia & The LymphomaSociety’s “Targets, (LLS) & Leads Targets, Leads, andCandidatesProgram Leukemia &LymphomaSociety: ensure that interests are throughout aligned process. the ofgoal generating areturn and re-investing projects innew to additional funding/exit. Accelerate maintain Chicago! will a implemented be will to drive toward milestones those and established,be and rigorous, disciplined project management Once aproject commercially is selected, driven milestones will development, and rapid acceleration of products to clinic. the universities into patients. selection, Their theaim critical is of novel biomedical technologies from major the Chicago area and time the resource associated barriers with translation the Accelerate Chicago!, an independent entity on decreasing focused Lifeof Chemistry TheProcesses Institute is establishing Accelerate Chicago! Chemistry ofLifeProcessesInstitute: Northwestern University Entrepreneur-in-Residence, P.Andrew Mazar PRESENTER: Celgene Corporation Research and Early Development, Executive Vice President, Global Daniel Tom Lymphoma Society MissionChief Officer,Leukemia & The Executive Vice President, J. DeGennaro Louis PRESENTERS:
EMPIRE BALLROOM I BALLROOM EMPIRE
ALVIN PROGRAM & ACTIVITIES PARTNERING FOR CURES 29 ALVIN
TUESDAY EMPIRE BALLROOM V
PRESENTER: PRESENTER: Alan Russell Career Distinguished Highmark University, Carnegie Mellon Professor, and Officer Chief Innovation and Allegheny President, Vice Executive Health Network PRESENTER: PRESENTER: Daniel R.Weinberger LieberInstitute CEO, & Director Development Brain for
Carnegie Mellon University/Highmark: Carnegie Mellon University/Highmark: Institute Disruptive Health Technology Allegheny and (CMU), Highmark, University Carnegie Mellon Technology Health the Disruptive created have Network Health aimed initiative million $11 a multi-year (DHTI), Institute accessibility and simplicity, the affordability, increasing at healthcare where environment an is DHTI healthcare. of to delivered rapidly and be can clinically tested innovations of the leading development are CMU researchers patients. delivery healthcare and biomedical, science, engineering, currently is DHTI colleagues. new with institute technologies medical behavior diagnostics, of accessibility on focusing improved mining, data disease management, chronic change, infection and ultrasound, diagnostic improved endoscopy, a large impact can that projects funds DHTI prevention. have and savings, healthcare substantial provide population, life. of quality and safety patient in improving success likely Lieber Institute for Brain Development Lieber Institute privately a (LIBD), Development Brain for Institute The Lieber affiliated Institution Research funded Maryland Medical epigenetic and genetic the defining is Hopkins, Johns with the deviations development, brain human of regulation the and disorders, brain developmental characterize that has LIBD drug development. for newof targets identification collection curated exquisitely an including resources, unique to fetal life early (from brains 1,000 human than more of neuropsychiatric with individuals of hundreds and age old hundreds including cell lines human of thousands disorders), large and in LIBD, are whose brains individuals from lines of clinical datasets. phenotyped extensively and
INNOVATOR PRESENTATION INNOVATOR INNOVATOR PRESENTATION INNOVATOR 11:15 AM AM - 11:40 11:15 11:15 AM AM - 11:40 11:15 30 PARTNERING FOR CURES PROGRAM & ACTIVITIES TUESDAY 11:45 AM - 12:40 PM -12:40 11:45 AM 11:45 AM - 12:40 PM -12:40 11:45 AM BREAKOUT PANEL BREAKOUT PANEL foundation, investors) areal possibility? Are syndicates of capital from differentsources (government, allowing Internet to the them use to mass-market to investors? significantsource new capitalof forearly-stage companies by into role the of risk-takers? Can crowdfunding a unlock greatlybeen exaggerated? Are of other types investors stepping Is eraof the venture capital over, or have reports of its death Beyond VentureCapital being delivered effectively efficiently?and ensuring that innovation is reaching patients and that care is therapies? Whatthe is role patientof first-in-class groups in for companies risky to areas tackle of and unmet need high innovation killer, as some fear, or can it adisruptive be driver it over the life cycle of apatient? Will on afocus an value be Who defines value, and how do capturewe growing. is trials opposed to “gold the standard” of randomized controlled unclear. Pressure from payers for “real-world evidence” as implications for research medical innovation are entirely “value” but its everywhere, definition is discussed theand As controlling costs has become central, concept the of The healthcare system is changing dramatically and quickly. Can ValueDriveInnovation? Reimbursement: of Technology Engineering, Massachusetts Institute Director, Laboratory for Financial Harris Professor, Professor of Finance; Castagnetti Inc. MODERATOR: AdvaMed Blue Cross and Blue Shield Association Council, Kaiser Permanente Robert J. Beall, Robert SPEAKERS: Gregory C.Simon,Gregory Paul M.Meister, W.Andrew Lo, Ganot, Ilan Borisy,Alexis SPEAKERS: Rosen, Dean Stephen J. Ubl, Ling, Shari Trent Haywood, Hiatt, Jo Carol Medicines Founder and Member Board at Blueprint former CEOat Warp Drive Bio; Co- Foundation Medicine; Chairman and Ventures; Chairman and Co-Founder, Cystic Fibrosis Foundation MODERATOR: inVentiv Health Medicaid Services Officer, Centers forMedicare & Deputy Medical Chief Co-CEO, Ventures Solid Partner, Mehlman Vogel Partner, Third Rock Charles E.and Susan T. President and CEO, Chair, National Product President and CEO, EMPIRE BALLROOM V BALLROOM EMPIRE EMPIRE BALLROOM I BALLROOM EMPIRE Chief Medical Chief Officer, Chairman and CEO, CEO, Poliwogg.com PROGRAM & ACTIVITIES PARTNERING FOR CURES 31 ALVIN Assistant Professor, Vice President President Vice EMPIRE BALLROOMEMPIRE Director, U.S. Centers Centers U.S. Director, TUESDAY Vice President, President, Vice Scientist, Sanaria Inc.; Inc.; Sanaria Scientist, Senior Vice President & President Senior Vice Chief Medical Officer, Officer, Chief Medical Founder, Koa Labs Koa Founder, Deputy Director for for Director Deputy Co-Founder and CEO, CEO, and Co-Founder Co-Founder, Microryza Co-Founder, Innovation and Networks, Ewing Marion Marion Ewing Networks, and Innovation Foundation Kauffman for Disease Control and Prevention and Disease Control for Chief Scientific Officer, Sanofi Chief Scientific Officer, Gary Nabel, J. Andy Palmer, Roni Zeiger, Lesa Mitchell, Jonathan Dordick, Sally Rockey, Cindy Wu, Adam Ruben, SPEAKERS: Thomas Frieden, Jeff Hammerbacher, SPEAKERS: SPEAKERS: Otis Brawley, MODERATOR: Extramural Research, National Institutes Institutes National Research, Extramural of Health Columnist, Science Careers Columnist, Smart Patients Smart MODERATOR: American Cancer Society Cancer American Genetics and Genomic Sciences, Mount Sciences, Genomic Mount Genetics and and Center; Medical Co-Founder Sinai Cloudera Chief Scientist, for Research and Howard P. Isermann Isermann P. Howard and Research for Biological Chemical and of Professor Polytechnic Rensselaer Engineering, Institute
The People Behind Science: Behind Science: The People for Food Will Work more for level the national at push intensifying an Despite and engineering, technology, (science, STEM better and scientists life young for prospects the career education, math) jobs in academic them for train We been worse. rarely have is Industry elsewhere. the jobs are of when medicine most with workers find it can’t yet says in droves off people laying scientists young train better we can skills.the right How ensure jobs to the right for competencies the right with generation the next keep we can How fruitful paths? career declining, are levels in the field when funding innovators of the next losing we Are investigators? young especially for of other the parts and fields other to scientists of generation offer? to solutions has Who world? BREAKOUT PANEL BREAKOUT Big Data is a big deal in just about every these lives about deal aspect our in just a big of is Data Big implications and promise its over fear and hype generating days, well- economic our to habits everything consumer our for from medical research and Healthcare personal privacy. our being to sciences in life data big of the reality is What exceptions. no are the tools have Dowe collecting data? the we right Are now? right questions useful What knowledge? into data necessary transform to big what and not, what’s working, What’s answer? seeking to we are can data big be need before to addressed challenges and questions bear fruit in medical research? Lunch Plenary Big Data Needs Big Ideas 1:00 PM - 2:30 PM 11:45 AM11:45 - 12:40 PM 32 PARTNERING FOR CURES PROGRAM & ACTIVITIES TUESDAY 2:45 PM - 4:40 PM -4:40 PM 2:45 Time EqualsLivesTalks PM -3:45 PM 2:45 Partnering &ExpertConsultations Each 10-minuteEach bring will to story life compelling the factors personal that come to play search inthe for cures. to pave path the toward solutions –sometimes against many odds. segmentThis featurewill remarkablewith incrediblespeakers stories to tell aboutwhat drivesthem to continue BOOTH/IMPERIAL/MOROSCO EMPIRE BALLROOM I BALLROOM EMPIRE THERAPEUTIC AFFINITY & RESEARCH BUILDING BLOCKS ROUNDTABLES
NOVEMBER 4, 2013 MONDAY ROUNDTABLES BLOCKS BUILDING & RESEARCH AFFINITY THERAPEUTIC
Therapeutic Affinity & Research Building Blocks Roundtables Start each Partnering for Cures day with an opportunity to network with peers who share your goals and interests. Therapeutic Affinity and Building Blocks Roundtables bring together meeting participants from various disciplines and sectors. With a common ground established, these informal gatherings can quickly turn into dynamic and productive conversations. Join the following roundtables: 7:00 AM - 8:00 AM EMPIRE BALLROOM TABLE TOPIC TABLE HOSTS Vaccines and preventive technologies Tomas Hode, CEO, Immunophotonics Kari Stoever, Vice President External Affairs, Aeras Immunotherapy Louise Perkins, Chief Science Officer, Melanoma Research Alliance Central nervous system-based diseases and conditions Kieran Breen, Director of Research and Innovation, Parkinson’s UK Genetic, rare diseases and conditions Mary Beth Kiser, President & CEO, Beyond Batten Disease Foundation PARTNERING FOR CURES FOR PARTNERING Alzheimer’s disease Keith Fargo, Director of Scientific Programs, Alzheimer’s Association Dean Hartley, Director of Science Initiatives, Medical and Scientific Relations, Alzheimer’s Association Autoimmune diseases Alice Bast, President, National Foundation for Celiac Awareness Ginger Spitzer, Executive Director, Foundation for Sarcoidosis Research Diabetes & metabolic diseases Cynthia Rice, Senior Vice President, Advocacy & Policy, JDRF Maria Vassileva, Senior Scientific Program Manager, Foundation for the National Institutes of Health Mental health diseases and conditions Darin Dougherty, Associate Professor, Harvard MGH Daniel Weinberger, CEO, Lieber Institute for Brain Development Oncology – Solid tumors Linda Molnar, Executive Consultant, LKM Strategic Consulting Oncology – Blood (hematologic) Eric Low, CEO, Myeloma UK Neuro-oncology Paul TonThat, CEO, National Brain Tumor Society 35 TUESDAY NOVEMBER 5, 2013
Therapeutic Affinity & Research Building Blocks Roundtables
7:00 AM - 8:00 AM EMPIRE BALLROOM TABLE TOPIC TABLE HOSTS Data sharing/Health IT Christopher Boone, Vice President, Avalere Health Finance and investing Andrew P. Mazar, Entrepreneur-in- Residence, Northwestern University Misha Tsirulnikov, Chief Operating Officer, BayBio Clinical trials Bray Patrick-Lake, Director of Stakeholder Management, Clinical Trials Transformation Initiative Crowdsourcing cures Christian Bailey, Founder, Curated Innovation Bernard Munos, Founder, InnoThink THERAPEUTIC AFFINITY & RESEARCH BUILDING BLOCKS ROUNDTABLES Diagnostics and devices Jessica Foley, Scientific Director, Focused Ultrasound Foundation Platform technologies Lu Alleruzzo, Chief Operating Officer, Immunophotonics, Inc. Robert Zivin, Research Associate Professor, Medicine, University of Miami Reimbursement strategies Kevin Grimes, Co-Director SPARK Program, Stanford University PARTNERING FOR CURES Brian Rosen, SVP Public Policy, The Leukemia & Lymphoma Society Multi-stakeholder collaborations Caren A. Heller, Associate Dean for Intercampus and Industry Initiatives, Weill Cornell Medical College Campus Mark Suto, VP Drug Discovery, Southern Research Institute Biomarker development Kimberly Myers, Manager, Deloitte Linda Tannenbaum, Executive Director, Open Medicine Foundation Investing in young investigators LeeAnn Bailey, Manager, Deloitte Elizabeth Schwarzbach, Director R&D Strategy Development, GlaxoSmithKline
36 PANELISTS
PANELISTS PARTNERING FOR CURES 39
MARGARET ANDERSON ANDERSON MARGARET FasterCures Executive Director, , FasterCures of director the executive is Anderson Margaret speed the to up works that Institute the Milken of a center discovery patients. to from go new to medicines for timeline the of past-president and member board a founding is She Initiative’s the eHealth co-chairs FDA, a Stronger for Alliance the of a member is and Research, and Data Council on National Center for Advancing Translational Sciences Advisory Translational Advancing for Center National Review Board, Network Acceleration theCouncil, Cures for United Directors, Council Board of Health the National of the Institute and Committee, Steering Research Medical and Development Drug Discovery, on Forum Medicine’s the at positions held Anderson Previously, Translation. Society Women’s for Development, Educational for Academy Association, Health Public American Research, Health Assessment. Technology of Office Congressional and —Margaret Anderson Engaged and empowered patients will drive the system to be more effective. They infuse urgency and focus on the true bottom line: finding a cure. I am optimistic because… PANELISTS
CECILIA ARRADAZA Director, Communications & Policy, FasterCures PARTNERING FOR CURES
What’s standing in the way: Cecilia Arradaza brings to FasterCures more than 15 years of experience in public relations, public affairs, and strategic communications on policy issues that impact medical research The challenge is and the life sciences industry. She joined FasterCures from getting people to think Chandler Chicco Agency (CCA), a pure-play health beyond the present, communications firm, where she developed public affairs programs for clients including Johnson & Johnson, the Robert to realize that this Wood Johnson Foundation, and VHA Inc. Before joining CCA, could happen to my Arradaza implemented strategic communications and issues child, my mother, my management initiatives for pharmaceutical and foundation brother, to me. clients of Hyde Park Communications; managed media relations and public education efforts for the American Psychiatric —Cecilia Arradaza Association; and was part of the health and international public affairs practices at Powell Tate. Arradaza began her health communications career at the National Osteoporosis Foundation.
Panel: The Other Translation Gap: Turning Outputs into Outcomes
40 PANELISTS PARTNERING FOR CURES FOR PARTNERING CHRISTOPHER AUSTIN Director, National Center for Advancing Translational Sciences
I am optimistic because… In September 2012, Christopher P. Austin was appointed the first permanent director of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes This is a time of of Health (NIH). Austin came to NIH in 2002 from Merck, unprecedented where his work focused on genome-based discovery of novel opportunity given targets and drugs. At NIH, he has been the senior advisor to the confluence of the director for translational research at the National Human Genome Research Institute, director of the Therapeutics for fundamental discovery, Rare and Neglected Diseases program, director of the NIH novel interventional Chemical Genomics Center, and scientific director of the technologies, and NIH Center for Translational Therapeutics. Austin earned a bachelor’s degree in biology from Princeton University and a appreciation by all medical degree from Harvard Medical School. parts of the medical R&D ecosystem that collaboration turbocharges translation. —Christopher Austin
Panel: The New Value Proposition for Academic Science
41 PANELISTS
ROBERT J. BEALL President and CEO, Cystic Fibrosis Foundation PARTNERING FOR CURES I am optimistic because… Robert J. Beall has worked for more than 30 years at the Cystic Fibrosis Foundation (CFF) to bring new therapies to patients. In 1988, CFF launched its groundbreaking Therapeutics With the current Development Program, a unique partnership among industry, state of biomedical academics, and CFF that fosters new approaches for CF drug research, where will discovery and development. There are now currently more than 30 potential therapeutic products in the pipeline. The foundation’s the industry look for model has been the subject of two case studies by the Harvard the next breakthrough Business School and documented in The New Yorker, Forbes, platform technologies and BusinessWeek. Beall previously served on the medical upon which to build school faculty of Case Western Reserve University and worked at the National Institutes of Health. He received his doctorate in the next generation biochemistry from the State University of New York at Buffalo. of drug discovery? —Robert J. Beall
Panel: Reimbursement: Can Value Drive Innovation?
42 PANELISTS PARTNERING FOR CURES FOR PARTNERING ROBI BLUMENSTEIN President, CHDI Management
In 2002, Robi Blumenstein organized CHDI Management to provide management services to nonprofit organizations engaged in Huntington’s disease research. Blumenstein began his career as a lawyer at Torys, a law firm in Toronto, before moving into merchant banking, where he was responsible for structuring and negotiating transactions and supervising investment analysis. He was a principal at First City Capital Corporation, CIBC Capital Partners, and MMC Capital. Prior to that, he built a harpsichord and was a director of Life Times Nine, a short subject film that was nominated for an Academy Award in 1973. Blumenstein graduated from the University of Toronto with a bachelor of arts and a law degree, and has a master of business administration degree from Harvard Business School.
Panel: Learning To Love Failure
43 PANELISTS
ALEXIS BORISY Partner, Third Rock Ventures; Chairman and Co-Founder, Foundation Medicine; Chairman and former CEO at Warp Drive Bio; Co-Founder and Board Member at Blueprint Medicines PARTNERING FOR CURES I am optimistic because… Alexis Borisy is a biotechnology entrepreneur with more than 20 years of experience building and operating science-based organizations. Borisy joined the life sciences venture capital firm We think this is a Third Rock Ventures as a partner in 2009. He also co-founded great time to invest in Foundation Medicine and served as the company’s interim CEO, early stage, because co-founded Blueprint Medicines, and launched and served as interim CEO and is chairman of Warp Drive Bio. Before joining we are backing the Third Rock Ventures, Borisy founded CombinatoRx and served science and drugs as its CEO. Borisy has been recognized for his achievements that matter. and has been bestowed many awards including being selected for Harvard’s Howard Hughes Predoctoral Fellowship, MIT’s —Alexis Borisy Technology Review Innovator of the Year, New England Entrepreneur of the Year in Life Sciences, and being named a Presidential Scholar. Borisy serves on the board of BIO, is an overseer at the Boston Museum of Science, is a co-founder and former chairman of FORMA Therapeutics, and serves on the board of Blueprint Medicines. Borisy’s undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work at Harvard University.
Panel: Beyond Venture Capital
44 PANELISTS PARTNERING FOR CURES FOR PARTNERING OTIS BRAWLEY Chief Medical Officer, American Cancer Society
Otis Brawley, a key leader in cancer research and education, is the chief medical officer of the American Cancer Society. He also currently serves as a professor of hematology, concology, medicine, and epidemiology at Emory University. Brawley is a member of the Centers for Disease Control and Prevention Advisory Committee on Breast Cancer in Young Women. Previously, Brawley has served as a member of the American Cancer Society’s Prostate Cancer Committee, co-chaired the U.S. Surgeon General’s Task Force on Cancer Health Disparities, served as medical director of the Georgia Cancer Center for Excellence at Grady Memorial Hospital in Atlanta, and deputy director for cancer control at Winship Cancer Institute at Emory University, and filled a variety of capacities at the National Cancer Institute. He was formerly a member of the Centers for Disease Control and Prevention Breast and Cervical Cancer Early Detection and Control Advisory Committee, the Food and Drug Administration Oncologic Drug Advisory Committee, and he chaired the National Institutes of Health Consensus Panel on the Treatment of Sickle Cell Disease. Brawley is a graduate of University of Chicago, Pritzker School of Medicine. He completed his internship at University Hospitals of Cleveland, Case-Western Reserve University, his residency at University Hospital of Cleveland, and his fellowship at the National Cancer Institute.
Panel: The People Behind the Science: Will Work for Food
45 PANELISTS
NANCY BROWN CEO, American Heart Association PARTNERING FOR CURES
I am optimistic because… Nancy Brown has been CEO of the American Heart Association (AHA) since 2009. The AHA is the world’s oldest and largest voluntary organization dedicated to fighting Our steadily increasing cardiovascular diseases and stroke. During Brown’s tenure, ability to analyze and the AHA has advanced its commitment to scientific discovery interpret genome- through the recently launched Science & Technology Accelerator, developed its first-ever integrated global strategy, based data offers and launched its Innovation Think Tank, which has created unlimited potential for numerous innovative business models to further AHA’s mission knowledge discovery and goals. Under her leadership, the association announced its in the fight against 2020 health impact goal: To improve the cardiovascular health of all Americans by 20 percent while reducing deaths from cardiovascular cardiovascular diseases and stroke by 20 percent. Prior to being diseases, stroke, and named CEO, Brown served as AHA’s chief operating officer for other major illnesses. eight years. She has been with the association since 1986. —Nancy Brown
Panel: Philanthropy: Investing for Impact In the Search for Cures
46 PANELISTS PARTNERING FOR CURES FOR PARTNERING WALTER CAPONE Chief Operating Officer, Multiple Myeloma Research Foundation
What’s standing in the way: As chief operating officer, Walter Capone oversees the core business and research operations of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Millions of dollars are Research Consortium. As part of the executive committee, spent yearly on cancer Capone is responsible for developing, designing, and research, yet the executing the innovative growth initiatives to accelerate new drug development and the scientific programs dedicated to structures and incentives overcoming myeloma. Capone has overseen the introduction to systematically share of NPO-driven expanded access programs, the launch of a and analyze data being landmark personalized medicine program, and the establishment generated are completely of a pre-competitive industry consortium to enable open access clinical and molecular “big data” internationally. Capone came inadequate—and it is to MMRF with more than 20 years of pharmaceutical and slowing down progress biotechnology leadership experience in the areas of commercial towards finding cures. development, operations, finance, marketing, and sales in the United States and internationally. —Walter Capone
Panel: The Art and Science of Multi-Stakeholder Collaboration
47 PANELISTS
WILLIAM CHIN Executive Vice President, Science and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America PARTNERING FOR CURES I am optimistic because… William Chin recently took on the role of executive vice president of science and regulatory affairs at Pharmaceutical Research and Manufacturers of America. Previously, he was We can create and the executive dean for research and Bertarelli Professor of implement effective Translational Medical Science at Harvard Medical School collaborative (HMS). Prior to HMS, Chin worked for the previous decade at Eli Lilly and Company, most recently as senior vice president partnerships now for Discovery Research and Clinical Investigation. He was also with focus across a faculty member at Brigham and Women’s Hospital and a multiple constituents Howard Hughes Medical Institute investigator. As a pioneering to improve vastly molecular endocrinologist at HMS, Chin embraced the early use of emerging DNA technology. He has published nearly our knowledge of 300 papers, chapters, and books. He is a graduate of Columbia human disease and College and Harvard Medical School. its translation into therapeutics that matter to our patients. —William Chin
Panel: Learning To Love Failure
48 PANELISTS PARTNERING FOR CURES FOR PARTNERING DAVID CLIFFORD Founder, Avicenna LLC
What’s standing in the way: Dave Clifford is a founder and senior partner at Avicenna, LLC. Avicenna is a strategic consulting firm based in Washington that assists federal, nonprofit, and industry stakeholders The single greatest navigate evolving research and development paradigms. challenge to the Prior to this role, he worked in public health and government medical R&D affairs for PatientsLikeMe. Previously, he spent six years working on cutting-edge research and development in biology, medicine, enterprise is a and neuroscience at the Defense Advanced Research Projects tendency to think Agency. He received his bachelor’s degree from the University pretty narrowly about of Maryland and his master’s degree in science and technology the experiences of policy from the George Washington University. people who want to participate in finding solutions for themselves and their loved ones. —David Clifford
Panel: Reducing Drag: New Approaches to IP Negotiation and Technology Licensing
49 PANELISTS
FRANCIS COLLINS Director, National Institutes of Health PARTNERING FOR CURES I am optimistic because… Francis Collins, a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the Human Genome Project, served as director of the National Human The unprecedented Genome Research Institute (NHGRI) at the National Institutes potential of current of Health (NIH) from 1993 to 2008. He is an elected member of biomedical research— the Institute of Medicine and the National Academy of Sciences. He is the recipient of the Presidential Medal of Freedom (2007) across all diseases, and the National Medal of Science (2009). In 2010, Collins was from basic to clinical— a co-recipient of the Albany Medical Center Prize in Medicine spurred on by new and Biomedical Research. Collins earned his bachelor’s degree technologies and the in chemistry at the University of Virginia, his doctorate in physical chemistry at Yale University, and his medical degree relentlessly innovative from the University of North Carolina. spirit of the scientific community. —Francis Collins
Panel: Big Science in the 21st Century
50 PANELISTS PARTNERING FOR CURES FOR PARTNERING MIKE COLLINS Vice President for Global Clinical Operations, Alexion Pharmaceuticals
In his current role, Mike Collins focuses on the development of drugs for ultra-rare diseases. Previously, he held leadership positions at Pfizer, including head of clinical operations, late-phase development operations, development operations, and global biometrics activities for two development programs. Prior to that, Collins was the head of biometrics at Hoechst UK and a statistician at the Hospital Centre in Stoke-on-Trent, providing statistical consultancy to a variety of healthcare professionals. His work-related interests include managing change, team leadership, outsourcing strategies, and operational delivery, as well as the implementation of innovative and standardized business processes for effective clinical research. He has a degree in genetics from the University of Sheffield and a master of science in applied genetics and a doctorate from the University of Birmingham.
Panel: Rare Diseases: Hot, but for How Long?
51 PANELISTS
ROBERT CONLEY Regulatory Leader, Biomedicines; Distinguished Lilly Scholar, Neurosciences, Eli Lilly and Company PARTNERING FOR CURES
Robert Conley leads the Late Phase Regulatory Science Group in Biomedicines for Eli Lilly. He is also a senior consultant for development in neuroscience and a member of the Bioethics Advisory Lead Committee. He is also an adjunct professor of psychiatry and affiliate professor of pharmacy practice and science at the University of Maryland. He has received many awards, including the Laughlin Award for Merit from the National Psychiatric Endowment Fund Fellowship, the Young Investigator Award from the International Congress on Schizophrenia Research, several Teacher of the Year awards, and an Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill. Conley received a bachelor of arts from the Johns Hopkins University and a medical degree from the University of Maryland School of Medicine.
Panel: FDA: Recalibrating the Benefit-Risk Equation
52 PANELISTS PARTNERING FOR CURES FOR PARTNERING ROBERT COOK-DEEGAN Institute for Genome Sciences & Policy and Sanford School of Public Policy, Duke University; FasterCures Senior Fellow
I am optimistic because… Bob Cook-Deegan was director for Genome Ethics, Law & Policy at the Duke Institute for Genome Sciences & Policy 2002-2012. He previously worked at the Institute Now we have to do of Medicine and National Academy of Sciences, and was a the important work: Robert Wood Johnson Health Policy Investigator at Georgetown studying the process University. Cook-Deegan was an AAAS Congressional Science & Engineering Fellow at the congressional Office of Technology of innovation in Assessment. He received his medical degree from the University genomics, the role of of Colorado and his bachelor’s degree in chemistry from intellectual property, Harvard College. and in particular, the practical value of a robust science commons. —Robert Cook-Deegan
Panel: Reducing Drag: New Approaches to IP Negotiation and Technology Licensing
53 PANELISTS
LOUIS J. DEGENNARO Executive Vice President and Chief Mission Officer, Leukemia and Lymphoma Society PARTNERING FOR CURES
What’s standing in the way: Louis J. DeGennaro’s responsibilities include oversight of all Leukemia & Lymphoma Society (LLS) mission functions, including patient services, public policy, and research, with the Ensuring equal access goal of effectively deploying resources in pursuit of the LLS to treatment: both mission. He has a successful record of bringing new drugs traditional access to the healthcare arena and has developed a strategy at LLS to accelerate the pace of turning academic research into issues (cost) and viable therapies to treat blood cancers. DeGennaro has been biases in providers appointed by the U.S. Secretary of Health and Human Services and variation in the to serve on the newly created National Center for Advancing speed of uptake of Translational Sciences Advisory Council and the Cures Acceleration Network Review Board at the National Institutes new therapeutics from of Health, and he serves on the Board of BioTheryX, Inc., bench to bedside. an early-stage biotechnology company. —Louis DeGennaro
Panel: The New Value Proposition for Academic Science
54 PANELISTS PARTNERING FOR CURES FOR PARTNERING LAURA DEMING Partner, The Longevity Fund
Currently a “Forbes 30 under 30” and partner at The Longevity Fund, Laura Deming has wanted to cure aging since the age of eight. After years working on nematode longevity at the University of California, San Francisco graduate school, Deming matriculated to MIT at 14 to work on artificial organogenesis and bone aging, and is now based in San Francisco, working to find and fund therapies to extend the human healthspan.
Panel: Five People Changing the Face of Bioscience
55 PANELISTS
JONATHAN DORDICK Vice President for Research and Howard P. Isermann Professor of Chemical and Biological Engineering, Rensselaer Polytechnic Institute PARTNERING FOR CURES
I am optimistic because… Jonathan Dordick has held chemical engineering faculty appointments at the University of Iowa (1987-1998) and Rensselaer Polytechnic Institute (1998-present) where he also The confluence of holds joint appointments in the departments of biomedical technology, ranging engineering, materials science and engineering, and biology. from high-quality, He is a fellow of the American Chemical Society, American Association for the Advancement of Science, and American patient-based data and Institute of Medical and Biological Engineers. He serves on the simulation-based high scientific advisory boards for several biotechnology companies performance computing and venture capital firms, and has cofounded a number of to high-throughput companies. Dordick has published more than 330 papers and is an inventor/co-inventor on nearly 40 patents and patent drug discovery will lead applications. He received his bachelor of arts in biochemistry to entirely new and and chemistry from Brandeis University and his doctorate in personalized treatments biochemical engineering from MIT. for improved patient outcomes. —Jonathan Dordick
Panel: The People Behind the Science: Will Work for Food
56 PANELISTS PARTNERING FOR CURES FOR PARTNERING GEOFF DUYK Partner and Managing Director, TPG Biotech
What’s standing in the way: Geoff Duyk is currently the partner and managing director at TPG Biotech. Previously, he was on the board of directors and was president of research and development at Exelixis, Inc., Lack of public and a scientific staff member at Millennium Pharmaceuticals, Inc., political conviction vice president of Genomics at Millennium Pharmaceutical regarding priority of Inc., an assistant professor at Harvard Medical School, and a co-principal investigator in the National Institutes of Health- science, reflected funded Cooperative Human Linkage Center. Duyk currently in waning scientific serves on the boards of directors of multiple companies. literacy and declining He graduated from Wesleyan University with a bachelor of arts financial support for in biology. Duyk holds a doctorate and medical degree from Case Western Reserve University and completed his medical and funding NIH and STEM fellowship training at University of California, San Francisco. education. —Geoff Duyk
Panel: FDA: Recalibrating the Benefit-Risk Equation
57 PANELISTS
CHRISTOPHER EGERTON-WARBURTON Partner, Lion’s Head Global Partners PARTNERING FOR CURES
What’s standing in the way: Christopher Egerton-Warburton is a leader in the field of innovative financing for health. Prior to establishing Lion’s Head, he spent 14 years at Goldman Sachs within the Debt Capital Markets group, Government where he was head of the sovereign, supranational, and agency team. intervention and While at Goldman Sachs he was the lead banker on a new multilateral grants alone are not development institution—The International Finance Facility for Immunisation—on behalf of the governments of France, Italy, Norway, sufficient to meet Spain, South Africa, Sweden, and the UK and most recently helped the funding gap in to design and is now running the Global Health Investment Fund, R&D for global health focused on R&D of new drugs, vaccines, and devices to address key diseases. global health diseases. Egerton-Warburton received a master of arts in biochemistry from Christ Church College at Oxford University. —Christopher Egerton-Warburton
Panel: Investing in Bioscience: Linking Financial, Human, and Social Returns
58 PANELISTS PARTNERING FOR CURES FOR PARTNERING STEVEN M. FERGUSON Deputy Director, Licensing and Entrepreneurship, Office of Technology Transfer, National Institutes of Health
I am optimistic because… Steven M. Ferguson is a registered patent agent and a certified licensing professional and a former chemist at the National Cancer Institute. He is faculty and Technology Transfer The success of Department chair at the Foundation for Advanced Education MenAfriVac in sub- in the Sciences Graduate School at the National Institutes of Saharan Africa Health (NIH) as well as an executive-in-residence at the Johns Hopkins University Carey School of Business. He has received really inspired us the AUTM President’s Award, the NIH Director’s Award, to the possibilities the FAES Instruction Award, the Federal Laboratory Consortium when working STEM Award, two “Deal of Distinction” awards from the with NGOs. We Licensing Executive Society, and 13 NIH Merit Awards. Steven M. Ferguson holds masters’ degrees in business can all now think administration from George Washington University and differently in terms chemistry from the University of Cincinnati. of commercialization strategies. —Steven M. Ferguson
Panel: Reducing Drag: New Approaches to IP Negotiation and Technology Licensing
59 PANELISTS
MARIA FREIRE President, Foundation for the NIH PARTNERING FOR CURES What’s standing in the way: Maria Freire was appointed president and executive director of Foundation for the National Institutes of Health (FNIH) in November 2012. FNIH draws together the world’s foremost In a time of researchers and resources in support of the mission of NIH. expanding scientific Prior to this appointment, Freire was the president of the opportunities and Albert and Mary Lasker Foundation. From 2001 to 2008, she was the president and CEO of the Global Alliance for shrinking research TB Drug Development. Freire also directed the Office of budgets, how can Technology Transfer at NIH from 1995 to 2001. Prior to that, we best collaborate she established the Office of Technology Development at the across sectors to University of Maryland. Freire obtained her bachelor of science from the Universidad Peruana Cayetano Heredia in and her advance biomedical doctorate in biophysics from the University of Virginia. discovery and innovation? —Maria Freire
Panel: The Art and Science of Multi-Stakeholder Collaboration
60 PANELISTS PARTNERING FOR CURES FOR PARTNERING THOMAS FRIEDEN Director, U.S. Centers for Disease Control and Prevention
What’s standing in the way: Tom Frieden is the director of the Centers for Disease Control and Prevention, our nation’s health protection agency. Since 2009, he has worked to control health threats from The single greatest infectious diseases, respond to emergencies, and battle the challenge facing leading causes of death in our nation and around the world. medical R&D is to He previously led New York City’s program that cut multidrug- resistant tuberculosis by 90 percent, and helped India prevent identify, validate, more than 3 million tuberculosis deaths. As New York City and scale up new health commissioner, he helped reduce teen smoking by half technologies which and adult smoking by one-third. add substantial health value for large numbers of patients. —Thomas Frieden
Panel: Big Data Needs Big Ideas
61 PANELISTS
STEPHEN FRIEND President, Sage Bionetworks PARTNERING FOR CURES I am optimistic because… Stephen Friend is president of Sage Bionetworks, a nonprofit biomedical research organization that aims to create a revolutionary open access approach to human biological With new tools comes information and the treatment of disease. Previously senior vice new understanding, president and franchise head for oncology research at Merck & and paradigms fall. Co., Friend led Merck’s basic cancer research efforts. Prior to that, he joined the Fred Hutchinson Cancer Research Center’s —Stephen Friend Seattle Project, an advanced institute for drug discovery. He has also held faculty positions at Harvard Medical School and Massachusetts General Hospital. He received a bachelor of arts in philosophy, a doctorate in biochemistry, and a medical degree from Indiana University.
Panel: Learning to Love Failure
62 PANELISTS PARTNERING FOR CURES FOR PARTNERING ILAN GANOT Co-CEO, Solid Ventures
What’s standing in the way: Ilan Ganot is the founder and co-CEO of Solid Ventures, a Cambridge, Mass.-based drug development company focused on Duchenne muscular dystrophy. Prior to starting up Solid, The greatest challenge he was an investment banker at JPMorgan Chase, Nomura is to de-risk early- Securities, and Lehman Brothers and lived and worked in stage science and London, Hong Kong, and New York. Ganot has a master of business administration degree from London Business School make it investable and law and business degrees from IDC in Herzliya, Israel. by the pharma and financial community. —Ilan Ganot
Panel: Beyond Venture Capital
63 PANELISTS
MICHEL GOLDMAN Executive Director, Innovative Medicines Initiative PARTNERING FOR CURES I am optimistic because… Michel Goldman currently serves as the executive director of the Innovative Medicines Initiative and a professor at the Universite Libre de Bruxelles. Previously, Goldman started the To reward those Institute for Medical Immunology as the first public-private who invest in large- partnership in the biomedical sector in Wallonia and was the scale collaborations, first vice-president of the BioWin Health Cluster created to foster networks among industries and academic institutions both in industry and in this region. He also has served on the European Research academia. Council as a member of the advisory panel on Immunology and Infectious Diseases. He received a medical degree in —Michel Goldman Brussels and a doctorate in immunology from the World Health Organization Immunology Research Centre in Geneva.
Panel: Big Science in the 21st Century
64 PANELISTS PARTNERING FOR CURES FOR PARTNERING JAMES C. GREENWOOD President & CEO, Biotechnology Industry Organization
I am optimistic because… James C. Greenwood is president and CEO of the Biotechnology Industry Organization (BIO), which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology There’s never been a centers, and related organizations. Since his appointment in better time for global January 2005, he has enhanced the trade association’s capacity biotech innovation – increasing both its staff and budget by nearly 50 percent. Greenwood represented Pennsylvania’s Eighth District in the because of the U.S. House of Representatives from January 1993 through incredible level of January 2005. A senior member of the Energy and Commerce scientific discovery. Committee, he was widely viewed as a leader on healthcare However, medical and the environment. Prior to his election to Congress, Greenwood served six years in the Pennsylvania General breakthroughs are Assembly (1981-86) and six years in the Pennsylvania being threatened Senate (1987-1992). Greenwood has a bachelor of arts in by changes in sociology from Dickinson College. reimbursement caused by budget pressures. —James C. Greenwood
Panel: The Art and Science of Multi-Stakeholder Collaboration
65 PANELISTS
JEFF HAMMERBACHER Assistant Professor, Genetics and Genomic Sciences, Mount Sinai Medical Center; Co-Founder and Chief Scientist, Cloudera PARTNERING FOR CURES
Jeff Hammerbacher is a founder and the chief scientist of Cloudera, and an assistant professor at the Icahn School of Medicine at Mount Sinai. Hammerbacher was an entrepreneur in residence at Accel Partners immediately prior to founding Cloudera. Before Accel, he conceived, built, and led the data team at Facebook. Before joining Facebook, Hammerbacher was a quantitative analyst on Wall Street. He earned his bachelor’s degree in mathematics from Harvard University
Panel: Big Data Needs Big Ideas
66 PANELISTS PARTNERING FOR CURES FOR PARTNERING KATHI E. HANNA Senior Fellow, FasterCures
I am optimistic because… Kathi E. Hanna, a FasterCures senior fellow, has more than 25 years of experience in science, health, and education policy. She served as research director for President Clinton’s National I am pinning my hopes Bioethics Advisory Commission and provides analytical and on young minds, our editorial services to the Presidential Commission for the Study intellectual capital. of Bioethical Issues. She currently consults to the Defense Health Board and the Office for Human Subjects Protections. In the I am convinced they 1990s, she served as senior advisor to the President’s Advisory are smarter and better Committee on Gulf War Veterans’ Illnesses and as the lead prepared to answer analyst and author for President Bush’s Task Force to Improve the hard questions. Health Care Delivery for Our Nation’s Veterans and the Task Force on the Future of Military Healthcare. In the 1980s and —Kathi E. Hanna 1990s, Hanna was a senior analyst at the congressional Office of Technology Assessment.
Panel: Mental Health: Research and Development at a Crossroads
67 68 PARTNERING FOR CURES PANELISTS for Cures for ImpactIntheSearch Philanthropy: Investing Panel: Garden,Cleveland Botanical Fieldstone Farms, New Directions, and Old Trail School. that have also from benefited the Harrington family’s generosity include The GatheringPlace, leadingthe mail-order provider supplies of medical specialty United inthe States. organizations Other Heart &Vascular Institute. Harrington is former the owner and CEOof Edgepark Medical Supplies, and Development. The Harrington family donatedalso $22.6million to establishthe UH Harrington establish Harrington the Institute, Discovery an integral of part The Harrington Project for Discovery variety of charitable causes. In 2012,The Harrington Family Foundation donated $50million to of BioMotiv. He, along with his family, has made many generous contributions over years the to a Ronald G.Harrington is aCleveland-area entrepreneur and philanthropist, and aboard member Chairman, BioMotiv Chairman, TheHarringtonFamilyFoundation; RONALD G.HARRINGTON
PANELISTS PARTNERING FOR CURES FOR PARTNERING TRENT HAYWOOD Chief Medical Officer, Blue Cross and Blue Shield Association
The Blue System is the nation’s largest health insurer covering nearly 100 million Americans. Trent Haywood supports BCBS companies’ record of innovation in communities around the country as they improve the choices of healthcare quality and patient safety for their members. Before joining BCBSA, Haywood served as senior vice president and chief medical officer for VHA Inc., where he developed best practices to drive quality, stimulate clinical innovation, support pay-for-performance, and prepare for consumer driven healthcare. Prior to joining VHA, Haywood was deputy chief medical officer for the Centers for Medicare and Medicaid Services. Haywood received a bachelor’s degree from the University of Notre Dame and a medical degree from the University of Illinois in Chicago. He also holds a law degree from Northwestern University School of Law.
Panel: Reimbursement: Can Value Drive Innovation?
69 PANELISTS
HUGH HEMPEL Co-Founder, Solution Therapeutics; Director and Patient Advocate, The Addi and Cassi Fund PARTNERING FOR CURES What’s standing in the way: Hugh Hempel is a patient advocate turned bio-entrepreneur. He currently serves as the co-founder and CEO of Solution Therapeutics; and co-founder and director of The Addi and Insurmountable NDA Cassi Fund. Previously, Hempel was the chief operating officer costs (timeframes) and co-founder of hopelink.com, director of online marketing are largely the result at Netscape Communications, manager of the engineering and science markets for Apple Inc., director of CDS 5000 for of our outdated Computervision, and marketing representative of national regulatory framework accounts for IBM. Hempel is also a board member of The Global that requires a truly Genes Project and on the advisory board of Spark Public systemic overhaul. Relations. Hempel received a bachelor of science in engineering The 2013 PDUFA/ management from the University of Vermont. FDASIA addressed very few of our real structural issues. —Hugh Hempel
Panel: FDA: Recalibrating the Benefit-Risk Equation
70 PANELISTS PARTNERING FOR CURES FOR PARTNERING MATTHEW HERPER Senior Editor, Forbes Magazine
I am optimistic because… Matthew Herper is currently a senior editor at Forbes Magazine. He has covered science and medicine from the Human Genome Project through Vioxx to the blossoming Patient groups are DNA technology changing the world today. He consistently filling a void in drug covers the biotechnology and pharmaceutical industry and research created is one of the most prominent journalists in this space. Herper received his bachelor of science from the Massachusetts by the industry’s Institute of Technology and his master of science in journalism legitimate fear of from Columbia University. failure. —Matthew Herper
Panel: Rare Diseases: Hot, but for How Long?
71 PANELISTS
SHARON HESTERLEE Vice President for Research, Parent Project Muscular Dystrophy PARTNERING FOR CURES What’s standing in the way: Sharon Hesterlee is the vice president of research for Parent Project Muscular Dystrophy, where she oversees research investment and strategy for the organization. Previously, A herd mentality has she spent 11 years with the Muscular Dystrophy Association led to companies and (MDA), where she established MDA Venture Philanthropy, investors stampeding designed to be a wholly owned subsidiary exclusively focused on the discovery and commercialization of therapies for in to the rare disease neuromuscular disease. In total, she has brokered and managed field—the herd may more than $30 million in drug development contracts with stampede out without industry and other partners. Hesterlee has also been involved appreciating the in the planning of numerous meetings on overcoming barriers nuances that can to therapy development in rare disease. lead to effective and profitable orphan products. —Sharon Hesterlee
Panel: Rare Diseases: Hot, but for How Long?
72 PANELISTS PARTNERING FOR CURES FOR PARTNERING JO CAROL HIATT Chair, National Product Council, Kaiser Permanente
Jo Carol Hiatt is chair of the National Product Council for Kaiser Permanente (KP) and also chairs KP’s Inter-Regional New Technologies Committee. She is a partner in Southern California Permanente Medical Group (SCPMG) and is assistant medical director, SCPMG Business Management. Hiatt chairs Southern California’s Technology Deployment Strategy Team as well as the Oversight Committee for Integrated Medical Imaging. She joined KP as a general surgeon in 1984, later serving as chief of surgery at Panorama City and member of the SCPMG board. Hiatt received her undergraduate degree from Stanford University, medical degree from Duke University, and master of business administration degree from the University of California, Los Angeles’ (UCLA) Anderson School of Management. She trained in general surgery at UCLA.
Panel: Reimbursement: Can Value Drive Innovation?
73 PANELISTS
PEARL HUANG Vice President, Global Head of Discovery Partnerships in Academia (DPAc), Alternative Discovery and Development, GlaxoSmithKline PARTNERING FOR CURES I am optimistic because… Pearl Huang has worked for GlaxoSmithKline (GSK) in a variety of roles, most recently joining Alternative Discovery and Development as the vice president, Global Head of We want to give all Discovery Partnerships in Academia (DPAc), where she is academic researchers responsible for building a discovery pipeline of medicines who are passionate with academic partners in all therapeutic areas and geographic locations. Previously, she also held roles at Merck and GSK. about translating In July 2010, Huang moved to Beijing to co-found BeiGene, their science into a China-based biotech focused on oncology drug discovery therapy a chance and development. During her time there, she built a discovery to collaborate and organization and pipeline, resulting in three patent filings “first in China” at the end of 2011. Huang has a bachelor’s degree in access GSK resources biology from MIT and a doctorate in molecular biology from and expertise to Princeton University. help bring novel and transformative treatments to patients. —Pearl Huang
Panel: The New Value Proposition for Academic Science
74 PANELISTS PARTNERING FOR CURES FOR PARTNERING ROBERT HUGIN CEO and Chairman, Celgene
Robert J. Hugin has been CEO at Celgene since 2010 and chairman since 2011. Since 1999, he has held many leadership positions at Celgene, including president, chief operating officer, director, senior vice president, and chief financial officer. Hugin is also chairman of the Pharmaceutical Research and Manufacturers of America. Previously, he was a managing director at J.P. Morgan & Co. Inc., which he joined in 1985. Hugin serves on the board of The Medicines Company, Atlantic Health System Inc., and Family Promise and is past chairman of the HealthCare Institute of New Jersey. He received a bachelor of arts degree from Princeton University and a master of business administration degree from the University of Virginia, and served as a United States Marine Corps infantry officer.
Panel: Investing in Bioscience: Linking Financial, Human, and Social Returns
75 PANELISTS
THOMAS R. INSEL Director, National Institute of Mental Health, NIH PARTNERING FOR CURES I am optimistic because… Thomas R. Insel is the director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health charged with generating the knowledge The development of needed to understand, treat, and prevent mental disorders. better therapeutics Over the past decade, his tenure at NIMH has supported large- will depend on better scale practical trials, increased its focus on autism, and put highest priority on applying new insights from genetics and diagnostics. More neuroscience to understanding mental disorders. Previously, precise diagnostic Insel was professor of psychiatry at Emory University and categories, based director of the Yerkes Regional Primate Research Center. on biomarkers, will He has published more than 250 scientific articles and four books, and has served on numerous academic, scientific, facilitate clinical and professional committees and boards. Insel graduated from trials and improve the combined B.A.-M.D. program at Boston University. clinical outcomes. —Thomas R. Insel
Panel: Mental Health: Research and Development at a Crossroads
76 PANELISTS PARTNERING FOR CURES FOR PARTNERING RAJIV KAUL Portfolio Manager, Select Biotechnology Portfolio and Advisor Biotechnology Fund, Fidelity Investments
Rajiv Kaul manages the Select Biotechnology Portfolio and Advisor Biotechnology Fund for Fidelity Investments. In his 17 years with Fidelity, Kaul has been widely recognized for his leadership within the biotech industry and often been ranked among the top U.S. health-care investors. This year, he won the Lipper Award for the best three-year risk-adjusted performance in his sector. He is a member of the Research Advisory Council at Massachusetts General Hospital, the teaching hospital for Harvard Medical School. Kaul worked at McKinsey & Co. prior to joining Fidelity. He is a graduate of Harvard University.
Panel: Investing in Bioscience: Linking Financial, Human, and Social Returns
77 78 PARTNERING FOR CURES PANELISTS forScience Academic Value New Proposition The Panel: inHanover,College New Hampshire. and MITTechnology the Review. Khamsi abachelor’s earned from degree inbiology Dartmouth research. Her articleshave appeared also inpublications such asEconomist, The Wired News, Khamsi worked as an online reporter for New Scientist, writing daily stories about biomedical Roxanne Khamsi is chief the editor news for Nature Medicine. Before joining Nature Medicine, Chief NewsEditor, NatureMedicine ROXANNE KHAMSI PANELISTS PARTNERING FOR CURES FOR PARTNERING RAJU KUCHERLAPATI Professor, Department of Genetics, Harvard Medical School
I am optimistic because… Raju Kucherlapati is the Paul C. Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham Get the best investors and Women’s Hospital. Kucherlapati was the first scientific with the most amount director of the Harvard Medical School-Partners Healthcare of experience in Center for Genetics and Genomics. His research focuses on gene mapping, gene modification, and cloning disease genes. starting something Kucherlapati has also taught at the Yeshiva University Albert new. You need people Einstein College of Medicine, the University of Illinois College with experience in of Medicine, and Princeton University. He received his bachelor finding those bumps of science and master of arts degrees in biology from universities in India, and he received his doctorate from the University of and how to navigate Illinois at Urbana. around them. —Raju Kucherlapati
Panel: Rare Diseases: Hot, but for How Long?
79 PANELISTS
STORY LANDIS Director, National Institute for Neurological Disorders and Stroke, NIH PARTNERING FOR CURES I am optimistic because… Story Landis is director of the National Institute for Neurological Disorders and Stroke (NINDS), which funds and conducts research aimed at reducing the burden of At NINDS we are neurological disorders, and chair of the NIH Stem Cell committed to reducing Task Force. She received her undergraduate degree from the burden of Wellesley College and her doctorate from Harvard University. After faculty appointments at Harvard and Case Western neurological disorders Reserve University, she joined NINDS in 1995 as scientific and have established director of the intramural program. As a bench scientist, translational programs she made fundamental contributions to our understanding and clinical trial of nervous system development. networks to allow investigators to work faster, better, and more efficiently toward achieving that goal. —Story Landis
Panel: Learning To Love Failure
80 PANELISTS PARTNERING FOR CURES FOR PARTNERING GEOFFREY LING Deputy Director, Defense Sciences Office, DARPA
What’s standing in the way: Geoffrey Ling is deputy director of the Defense Sciences Office at the Defense Advanced Research Projects Agency, The single greatest attending neuro critical-care physician at Johns Hopkins Hospital, and science division assistant director for medical challenge to the medical innovation at the White House Office of Science and R&D enterprise is Technology Policy. Ling recently retired from the Army providing appropriate Medical Corps after 27 years of service. He has published more than 150 peer-reviewed journal articles, reviews, incentives to innovators and book chapters. Ling has served on numerous committees, to remain committed including the National Institutes of Health-National Institute to R&D. of Neurological Disorders and Stroke Advisory Council and the executive board of the Neuro Critical Care Society. —Geoffrey Ling He received his bachelor of arts from Washington University, his doctorate in pharmacology from Cornell University, and his medical degree from Georgetown University.
Panel: Five People Changing the Face of Bioscience
81 PANELISTS
SHARI LING Deputy Chief Medical Officer, Centers for Medicare & Medicaid Services PARTNERING FOR CURES
Shari Ling is currently the Centers for Medicare and Medicaid Services (CMS) deputy chief medical officer. Ling has a special interest in the care of persons with multiple chronic conditions and functional limitations and reducing health disparities. Ling represents CMS on various Health and Human Services (HHS) workgroups, including the HHS National Alzheimer’s Project Act. After completing her medical degree, Ling served on the faculty of Johns Hopkins University School of Medicine and continues to teach there and at the University of Maryland. Ling is a geriatrician and rheumatologist who received her medical training at Georgetown University School of Medicine.
Panel: Reimbursement: Can Value Drive Innovation?
82 PANELISTS PARTNERING FOR CURES FOR PARTNERING ANDREW W. LO Charles E. and Susan T. Harris Professor, Professor of Finance; Director, Laboratory for Financial Engineering, Massachusetts Institute of Technology
What’s standing in the way: Andrew W. Lo’s research is focused on the fundamental aspects of investments and financial markets, including measuring illiquidity risk in hedge-fund returns, the growth Lack of funding of systemic risk in the hedge-fund industry, and evolutionary and insufficiently and neurobiological models of individual risk preferences and flexible business financial markets. He has published numerous articles and is a co-author of The Econometrics of Financial Markets, models in which the A Non-Random Walk Down Wall Street and The Evolution of availability of funding Technical Analysis, and author of Hedge Funds: An Analytic drives scientific and Perspective. He is currently a co-editor of the Annual Review translational medical of Financial Economics and an associate editor of the Financial Analysts Journal, the Journal of Portfolio Management, and the agendas rather than Journal of Computational Finance. the reverse. —Andrew Lo
Panel: Beyond Venture Capital
83 PANELISTS
JAY LOMBARD Chief Scientific Officer and Medical Director, Genomind PARTNERING FOR CURES I am optimistic because… Jay Lombard is responsible for Genomind’s scientific research and development, as well as medical leadership and clinical oversight. He has had numerous television and radio Biomarkers will appearances as well as given a talk at TEDMED 2012. Prior to help elucidate founding Genomind, Lombard served as the chief of Neurology the fundamental at Bronx Lebanon Hospital where he led the Stroke Unit. He is also a former assistant professor of neurology at New pathophysiology of York Presbyterian Hospital, clinical instructor of Neurology difficult-to-treat brain and Medicine at Albert Einstein College of Medicine, and disorders and thereby chief of Neurology at Westchester Square Medical Center and provide the required the Brain Behavior Center. Lombard is a graduate of Nova Southeastern University College of Osteopathic Medicine. platform to develop He combined his psychiatry and neurology residency training etiologically specific at Long Island Jewish Medical Center. treatment modalities. —Jay Lombard
Panel: Mental Health: Research and Development at a Crossroads
84 PANELISTS PARTNERING FOR CURES FOR PARTNERING PETER MARGOLIS Professor of Pediatrics and Director of Research, James M. Anderson Center for Health Systems Excellence, Cincinnati Children’s Hospital Medical Center
What’s standing in the way: Peter Margolis’ work encompasses the application and study of quality improvement methods in a broad range of areas including primary and sub-specialty care, communities, We need to ‘play and public health settings to improve the health outcomes the whole game’ of children, families, and communities. In 2006, Margolis joined by aligning all the Cincinnati Children’s Hospital Medical Center to create a new center focused on health care quality. He has worked extensively phases of research— with the certifying boards and specialty societies to assist them from discoveries in in designing programs that will enable physicians to meet the lab to translation new Maintenance of Certification requirements focused on of results reliably systems thinking and performance in practice. He is principal investigator of an NIH Roadmap transformative research grant into practice so all on redesigning systems for chronic illness care. patients benefit. —Peter Margolis
Panel: The Other Translation Gap: Turning Outputs into Outcomes
85 PANELISTS
JUSTIN MCCARTHY Senior Vice President & General Counsel, Worldwide Research & Development, Pfizer PARTNERING FOR CURES
I am optimistic because… Justin McCarthy is a senior vice president and associate general counsel at Pfizer Inc. and is the chief counsel for Pfizer’s Worldwide Research and Development division. He is The rapid acceleration responsible for coordinating legal support for the company’s of a networked R&D research activities and external collaborations across R&D, ecosystem that and leads a clinical trial platform that supports Pfizer’s clinical trial activities across all of Pfizer’s business units. As part of this fosters innovative role, McCarthy is leading an industry-wide initiative focusing collaborations among on improving public trust in industry-sponsored clinical trials. industry, governments, Prior to joining Pfizer, McCarthy was an associate in the law academia, patients, firm of Keller & Heckman. He holds a bachelor of science in pharmacy from the University of Rhode Island and a law and foundations to degree from the Catholic University of America. solve complex medical problems and advance science. —Justin McCarthy
Panel: Reducing Drag: New Approaches to IP Negotiation and Technology Licensing
86 PANELISTS PARTNERING FOR CURES FOR PARTNERING HOWARD MCLEOD Medical Director, Personalized Medicine Institute, Senior Member, Division of Population Sciences, Moffitt Cancer Center
I am optimistic because… Howard McLeod is medical director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center and senior member in the Department of Cancer Incorporation of a Epidemiology. McLeod has authored more than 350 peer- patient’s willingness reviewed papers on pharmacogenomics, applied therapeutics, for risk needs to and clinical pharmacology. He is a member of the National Institutes of Health Pharmacogenomics Research Network and become part of the Food and Drug Administration Pharmaceutical Science the development and Clinical Pharmacology Advisory Committee. Previously, process. Current McLeod served as the founding director of the University of strategies consider North Carolina at Chapel Hill’s Institute for Pharmacogenomics and Individualized Therapy and as a professor of pharmacy risk and benefit, but and medicine. He graduated from the Philadelphia College not together. We don’t of Pharmacy and Science and completed research fellowship need crazy, but we do training in cancer pharmacology at St. Jude Children’s Research need balance. Hospital and University of Glasgow. —Howard Mcleod
Panel: FDA: Recalibrating the Benefit-Risk Equation
87 PANELISTS
BETH MEAGHER Director, Strategy & Operations, Deloitte Consulting LLP PARTNERING FOR CURES
I am optimistic because… Beth Meagher leads the Translational Science practice at Deloitte Consulting. She has expertise in standing up and managing models of collaboration involving stakeholders The ability to across multiple sectors. In addition, she is a change agent harness the power of that enables organizations to define their collaboration technology, disruptive needs, establish goals, and identify the right mechanisms to further support collaboration. Meagher has a passion for the innovation, and deeply implementation of collaborative models and understands motivated researchers the importance of metrics and monitoring of collaborative and leaders provides mechanisms. Her distinguished career includes serving as a future that is ripe senior associate at Booz Allen Hamilton and serving in Teach for America. She holds a bachelor of arts in communication with possibility. studies and entrepreneurial studies from Muhlenberg College and a master of arts in organization effectiveness & policy —Beth Meagher studies from George Washington University.
Panel: The Art and Science of Multi-Stakeholder Collaboration
88 PANELISTS PARTNERING FOR CURES FOR PARTNERING PAUL MEISTER Chairman and Chief Executive Officer, inVentiv Health
What’s standing in the way: Paul M. Meister is chairman and CEO of inVentiv Health, Inc. a provider of commercial, consulting, and clinical research services to the pharmaceutical and biotech industries. He also The greatest is co-founder and CEO of Liberty Lane Partners, LLC, a private challenge facing investment company with diverse investments in healthcare. medical R&D is the Meister has also served in various roles at Thermo Fisher inability to facilitate Scientific Inc., a scientific instruments, equipment, and supplies company. Prior to Fisher Scientific, Meister held executive change. Technology positions with the Henley Group, Wheelabrator Technologies and creativity are and Abex, Inc. Meister is a director of LKQ Corporation, Inc. abundant, yet the R&D During the past five years, he also served as a director of M & F enterprise struggles Worldwide Corp. with early adoption of innovation that could significantly increase efficiencies in clinical development. —Paul Meister Panel: Beyond Venture Capital
89 PANELISTS
MICHAEL MILKEN Chairman, Milken Institute; Founder, FasterCures PARTNERING FOR CURES
I am optimistic because… Mike Milken has been at the forefront of a wide range of initiatives that have influenced public policy, accelerated medical research, supported public health and expanded Medical research access to capital. Fortune magazine called him “The Man and public health Who Changed Medicine” for “shaking up the medical offer abundant hope establishment and saving lives.” He is chairman of the Milken Institute and FasterCures, founder of the Melanoma Research and opportunity. Alliance, and the inspiration behind several philanthropic Investments in the initiatives worldwide. In 1982, Mike co-founded the Milken nation’s health Family Foundation, which supports education reform and produce the greatest research on a wide range of life-threatening diseases. As a financier, he is often said to have revolutionized modern returns in reduced capital markets by expanding access to capital for more suffering, longer than 3,200 growing companies that created millions of jobs. lives, lower costs and He graduated with highest distinction from UC Berkeley and earned his M.B.A. at the Wharton School. Mike and his wife economic growth. of 45 years, Lori, have three children and eight grandchildren. —Michael Milken More details are at www.mikemilken.com.
Panel: Investing in Bioscience: Linking Financial, Human, and Social Returns
90 PANELISTS PARTNERING FOR CURES FOR PARTNERING LESA MITCHELL Vice President, Innovation and Networks, Ewing Marion Kauffman Foundation
What’s standing in the way: Lesa Mitchell is vice president of Innovation and Networks at the Ewing Marion Kauffman Foundation. Her responsibilities include identification of programmatic and policy levers that The greatest challenge can accelerate innovation and support networks enabling firm to the R&D enterprise growth. Mitchell was instrumental in founding the Kauffman is overcoming barriers Innovation Network/iBridge Network, the Translational Medicine Conferences in the United States and Europe, and the National of access—to failed Academies-based University–Industry Partnership. She leads the trials data or academic replication of innovator-based commercialization and mentor datasets, to customers programs across the United States. An entrepreneur focused on across the supply global management of electronic clinical trials, Mitchell spent chain, and to the 20 years in global executive roles at Aventis and Quintiles. codified best treatment at an affordable cost. —Lesa Mitchell
Panel: Big Data Needs Big Ideas
91 PANELISTS
BOB MORE Head of Venture Investing, Bill & Melinda Gates Foundation PARTNERING FOR CURES
What’s standing in the way: Bob More is the head of venture investing for the Bill & Melinda Gates Foundation and leads the Global Health Venture Initiative. Prior to his current position, More was a general partner at The single greatest Frazier Healthcare and a member of the firm’s Biopharma Venture obstacle/challenge Team. His other previous positions include partner at Domain to the medical R&D Associates, a Kauffman Fellow, chief operating officer of Small Molecule Therapeutics, and positions at Pharmacia Biotech, enterprises is our Somatogen, and MedVest. More serves as an advisory board collective tendency to member for Greenspring Associates, Okapi Ventures, over promise based BioMed Realty Trust, The Medical Industry Group of the on our belief that the NVCA, and The Sulpizio Family Cardiovascular Center. He received a master of business administration degree from latest developments the Darden School of Business Administration at the University ‘complete’ our of Virginia and a bachelor of arts from Middlebury College. understanding of biology. —Bob More
Panel: Philanthropy: Investing for Impact In the Search for Cures
92 PANELISTS PARTNERING FOR CURES FOR PARTNERING GARY J. NABEL Senior Vice President & Chief Scientific Officer, Sanofi
Before joining Sanofi, Gary Nabel served as director of the Vaccine Research Center of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases. Prior to that, he served as the Henry Sewall Professor of Internal Medicine, professor of biochemistry, and Howard Hughes Medical Institute Investigator at the University of Michigan. In addition, Nabel served as the director of the Center for Gene Therapy and co-director of the Center for Molecular Medicine at the University of Michigan. In recognition of his expertise at the forefront of virology, immunology, gene therapy, and molecular biology, Nabel was elected as a member of the Institute of Medicine of the National Academy of Sciences in 1998. He received a doctorate and medical degree from Harvard University.
Panel: Big Data Needs Big Ideas
93 PANELISTS
LITA NELSEN Director, Technology Licensing Office, Massachusetts Institute of Technology PARTNERING FOR CURES What’s standing in the way: Lita Nelsen is the director of the Technology Licensing Office at MIT, where she has been since 1986. Each year, this office manages more than 600 new inventions, negotiates more than The single greatest 100 licenses, and helps to start 25 new startups. Previously, challenge from our she spent 20 years in industry, primarily in the fields of perspective is the membrane separations, medical devices, and biotechnology. Nelsen is widely published in the field of technology transfer lack of funds to and university/industry collaborations. She is a co-founder move “university of Praxis, the UK University Technology Transfer Training stage” technology Programme for which she was made a Member of the British to the (much later) Empire. Nelsen earned a bachelor of science and a master of science in chemical engineering from MIT and a master of stage of development science in management from MIT as a Sloan Fellow. that companies and venture investors now require before investing. —Lita Nelsen
Panel: Reducing Drag: New Approaches to IP Negotiation and Technology Licensing
94 PANELISTS PARTNERING FOR CURES FOR PARTNERING ANDY PALMER Founder, Koa Lab; Co-founder, Data Tamer
What’s standing in the way: Andy Palmer is a serial entrepreneur who specializes in accelerating the foundation and growth of early-stage, mission-driven companies. He has helped start, fund, The single greatest or found more than 30 innovative companies in technology, challenge to medical healthcare, and the life sciences. Palmer is also founder of Koa R&D is the lack of Labs, a start-up club in Harvard Square. Palmer has a particular interest in projects at the intersection of computer science modern Internet and the life sciences, and a specific passion for cancer drug and Web-based discovery and development. He helped found or held leadership systems that enable positions at Infinity Pharmaceuticals, Novartis Institutes for secure and direct Biomedical Research, Vertica Systems, Bowstreet, pcOrder. com, and Trilogy. Most recently, Palmer co-founded Data- collaboration Tamer with Dr. Michael Stonebraker of MIT. Palmer earned among researchers, his master of business administration from Dartmouth College institutions, and and undergraduate degrees from Bowdoin College. patients. —Andy Palmer
Panel: Big Data Needs Big Ideas
95 PANELISTS
MATTHEW PERRY Portfolio Manager, BVF Partners L.P. PARTNERING FOR CURES
I am optimistic because… Matthew Perry is the portfolio manager of BVF Partners L.P., a private investment partnership that manages funds with collective assets of $800 million. The funds focus on small-cap, Incredible advances in value-oriented investments. Prior to joining BVF, Perry worked identifying essential with Feinstein & Partners, a consulting firm with an emphasis molecular targets on investor relations for emerging healthcare companies focused on the development and commercialization of therapeutic combined with a products. He was simultaneously working with Feinstein & renewed enthusiasm Partners’ affiliate, Kendall Strategies, a business development from investors willing and strategy consulting firm assisting biotechnology and to fund earlier stage pharmaceutical companies. Before that, Perry monitored the biotechnology sector through an active investment program. research platforms He is also a co-founder and director of Nordic Biotech Advisors makes me very ApS. He holds a bachelor of science degree in biology from the optimistic about College of William and Mary. the future of drug discovery. —Matthew Perry
Panel: Rare Diseases: Hot, but for How Long?
96 PANELISTS PARTNERING FOR CURES FOR PARTNERING RICHARD POPS Chairman and CEO, Alkermes
I am optimistic because… Richard Pops serves as chairman and CEO of Alkermes. He took the CEO job at the age of 28, built it from 20 employees to more than 400, and made it profitable by the end of his 16-year The confluence run in 2007. He returned two years later as CEO to build of contemporary Alkermes even further. Under his leadership, it has grown scientific insight and to an international, publicly traded biopharmaceutical company with more than 1,200 employees and a portfolio sharper focus on of more than 20 commercial products. Prior to Alkermes, developing medicines Pops was vice president at PaineWebber Development with real medical and Corporation. Pops serves on the boards of Neurocrine economic value gives Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization, and the Pharmaceutical Research me great optimism and Manufacturers of America. Pops received a bachelor of for the future of R&D arts in economics from Stanford University. innovation across a wide spectrum of diseases. —Richard Pops
Panel: Big Science in the 21st Century
97 PANELISTS
ARATI PRABHAKAR Director, DARPA PARTNERING FOR CURES
I am optimistic because… Arati Prabhakar has spent her career investing in world- class engineers and scientists to create new technologies and businesses. Her first service to national security started in 1986 We are building a when she joined the Defense Advanced Research Projects future in which we Agency (DARPA) as a program manager. She moved on to be can outpace the the founding director of DARPA’s Microelectronics Technology Office. In 1993, President Clinton appointed Prabhakar to spread of infectious director of the National Institute of Standards and Technology. disease, collapse She then moved to Silicon Valley to work at a variety of start- clinical trial time, ups and as a partner with U.S. Venture Partners. Prabhakar was and understand brain appointed director of DARPA in 2012. She received a master of science in electrical engineering and doctorate in applied function. That’s what physics from the California Institute of Technology. possible as biology becomes technology. —Arati Prabhakar
Panel: Big Science in the 21st Century
98 PANELISTS PARTNERING FOR CURES FOR PARTNERING KATE RAWSON Senior Editor, RPM Report
I am optimistic because… Kate Rawson is a contributing editor at Prevision Policy and senior editor at The RPM Report. She was previously a reporter and editor at The Pink Sheet, where she covered drug regulation FDA leadership is and reimbursement issues. During her 10-year tenure at FDC becoming a true Reports, she helped launch The Pink Sheet DAILY, and also partner to industry served as managing editor of The Rose Sheet, which covers in developing new regulatory and business news of the cosmetics industry. treatments. The new ‘breakthrough’ therapies program is especially exciting, with the potential to shave years off the development timeline for qualifying products. —Kate Rawson
Panel: FDA: Recalibrating the Benefit-Risk Equation
99 PANELISTS
JESSICA RICHMAN Co-Founder and CEO, uBiome PARTNERING FOR CURES
I am optimistic because… Jessica Richman started and sold her first company after high school. At Stanford University, she earned degrees in economics and interdisciplinary engineering. Richman arrived at Oxford We are moving University as a Clarendon Scholar and completed a master of toward a system science degree at the Oxford Internet Institute. She is currently with the individual a doctorate in philosophy student at Oxford with a focus on innovation, social networks, and collective intelligence. at the center, where Richman is a co-founder of uBiome, the world’s largest they belong. Instead crowdfunded citizen science startup. uBiome has been featured of just focusing in Wired, MIT Technology Review, Scientific American, on “patients,” NPR, FoxNews, ABC News, and dozens of other media outlets. She has spoken at TEDMED, SciFoo, Oxford University, “providers,” and and many other conferences and universities. “payers,” we can focus on people joining together to help themselves. —Jessica Richman
Panel: Five People Changing the Face of Bioscience
100 PANELISTS PARTNERING FOR CURES FOR PARTNERING ROBERT RING Chief Science Officer, Autism Speaks
Rob Ring is the chief science officer at Autism Speaks and also serves as president of Delivering Scientific Innovation for Autism, the venture philanthropy arm of Autism Speaks that is helping to facilitate translational activities in the for-profit sector required to develop commercial products that will improve the quality of life and health for individuals with autism. Prior to joining Autism Speaks, Ring served as senior director and head of the Autism Research Unit at Pfizer Worldwide Research and Development and worked for more than 10 years in psychiatric medicines discovery and development at Wyeth Research. Ring earned a bachelor of arts in both fine art and biology from Westmont College and a doctorate in molecular neurobiology from City of Hope.
Panel: Mental Health: Research and Development at a Crossroads
101 PANELISTS
SALLY ROCKEY Deputy Director for Extramural Research, National Institutes of Health PARTNERING FOR CURES
I am optimistic because… Sally Rockey oversees the development and implementation of policies governing biomedical research supported by the National Institutes of Health (NIH) across the country We are a technology and around the world, a position she has held since 2005. and technologically Previously, she was the deputy administrator and chief based economy— information officer at the U.S. Department of Agriculture’s innovation-based. Our extramural research arm, where she aligned information technologies with the department’s goals. Rockey is a frequent investment in science is public speaker, giving presentations on extramural research even more critical now priorities and policies, grantsmanship, the competitive peer- to take full advantage review process, scientific integrity, and IT. She leads or is active of technological on a number of federal committees related to science, federal advancements that research assistance, and electronic government. She received are coupled with fuller her doctorate in entomology from The Ohio State University. understanding of fundamental biological processes. —Sally Rockey Panel: The People Behind the Science: Will Work for Food
102 PANELISTS PARTNERING FOR CURES FOR PARTNERING DEAN ROSEN Partner, Mehlman Vogel Castagnetti Inc.
I am optimistic because… Dean Rosen provides policy counsel and strategic advice to policy makers, business leaders, trade association executives, and nonprofit organizations on a broad range of health issues. The greatest He has represented major health systems, physician specialty threat to continued organizations, private health plans, clinical laboratories, advances in medical biotechnology companies, pharmaceutical manufacturers, and national employers seeking to comply with the Patient R&D is the broader Protection and Affordable Care Act and affect national health reimbursement policy. Previously, Rosen was the chief healthcare advisor climate, the growth in to Senate Majority Leader William Frist and the senior overall health costs, vice president of policy and general counsel for the Health Insurance Association of America. He also served as majority and the resulting counsel for the House Ways and Means Health Subcommittee imperative toward and health policy coordinator and majority counsel to the cost containment in Senate Committee on Labor and Human Resources. healthcare. —Dean Rosen
Panel: Reimbursement: Can Value Drive Innovation?
103 104 PARTNERING FOR CURES PANELISTS Collaboration of Multi-Stakeholder The ArtandScience Panel: Pharmaceuticals,Radius and Theracrine. boards biotechnology ofadvisory several companies and is ascientific founder of ProScript, at Massachusetts the Hospital. General on He board the of has directors served and scientific development team for alendronate (FOSAMAX®).Earlier, he was chief of Unit Endocrine the Previously, he was senior president vice for research at Merck where worldwide the he co-led Center, and director of Harvard-MIT the Division of Health and Sciences Technology. Professor of Medicine at Harvard Medical School,president Israel of Beth Deaconess Medical Rosenblatt previously was dean of Tufts UniversitySchool of GeorgetheMedicine, R. Minot Merck’s advocate external primary on issues medical and represents voice the of patient. the Scientist, educator, hospital and healthcare global company executive, Michael Rosenblatt is Officer, Merck Executive VicePresidentandChiefMedical MICHAEL ROSENBLATT
PANELISTS PARTNERING FOR CURES FOR PARTNERING ADAM RUBEN Scientist, Sanaria Inc.; Columnist, Science Careers
What’s standing in the way: Adam Ruben is a writer, comedian, storyteller, and molecular biologist. For more than a decade, he has performed at clubs, colleges, and private venues across the country, including at Our biggest obstacle some of the best-known storytelling shows and comedy clubs. in medical research is He is the author of Surviving Your Stupid, Stupid Decision to inertia. We must feel Go to Grad School, a satirical guide to the low points and, well, lower points of post-baccalaureate education. Additionally, free to abandon failing he is a molecular biologist working to develop a malaria vaccine projects, even if we’ve at Sanaria, Inc. convinced someone to give us money to work on them. —Adam Ruben
Panel: The People Behind the Science: Will Work for Food
105 PANELISTS
JOE V. SELBY Executive Director, Patient-Centered Outcomes Research Institute PARTNERING FOR CURES
Joe V. Selby is the first executive director of the Patient-Centered Outcomes Research Institute (PCORI), where he works to identify and address strategic issues and opportunities for PCORI and to implement and administer the research agenda authorized by the PCORI Board of Governors. Selby joined PCORI from Kaiser Permanente, Northern California, where he was a researcher for 27 years. Selby was elected to membership in the Institute of Medicine in 2009. He received his medical degree from Northwestern University, his training in family medicine from Contra Costa County Family Medicine Program, and his master’s in public health from the University of California, Berkeley. He served as a commissioned officer in the Public Health Service from 1976 to 1983 and received the Commissioned Officer’s Award in 1981.
Panel: The Other Translation Gap: Turning Outputs into Outcomes
106 PANELISTS PARTNERING FOR CURES FOR PARTNERING GREGORY C. SIMON CEO, poliwogg.com
I am optimistic because… Greg Simon is the CEO of Poliwogg and a board member of FasterCures. Poliwogg is an online crowd-financing marketplace that matches young companies with sophisticated By letting people put investors, concentrating on healthcare, yield-based investments, their money where and community enterprises. Previously, Simon was founding their passions are, president of FasterCures, held senior positions in both chambers of Congress and the Clinton administration, was a senior we can prove that strategy consultant to a variety of international technology The Best Is Yet To Fund CEOs, and served as Pfizer’s senior vice president for worldwide in health and health policy and patient engagement. care innovation. —Gregory C. Simon
Panel: Beyond Venture Capital
107 PANELISTS
JOSH SOMMER Executive Director, Chordoma Foundation PARTNERING FOR CURES What’s standing in the way: Diagnosed with chordoma, Josh Sommer spent two years learning the challenges faced by chordoma researchers—insufficient funding; scarcity of tissue, cell lines, and animal models; Organizations and isolation from other researchers. To solve these problems representing the and proactively advance the search for a cure, he co-founded interests of patients the Chordoma Foundation. Under Sommer’s leadership, the foundation has united and expanded the chordoma research whose only measure community and vastly accelerated the pace of chordoma research. of success is bringing As executive director, Sommer works with the foundation’s new treatments to research partners, advisors, and supporters to design, execute, market quickly are and fund research initiatives focused on developing new playing an increasingly treatments for chordoma. important role in driving medical research. —Josh Sommer
Panel: Reducing Drag: New Approaches to IP Negotiation and Technology Licensing
108 PANELISTS PARTNERING FOR CURES FOR PARTNERING MELISSA STEVENS Deputy Executive Director, FasterCures
I am optimistic because… Melissa Stevens is deputy executive director of FasterCures/ The Center for Accelerating Medical Solutions. She manages the planning and implementation of the organization’s Novel solutions are programs and priorities. She also directs the organization’s rising to the top— medical philanthropy efforts including the Philanthropy from innovative Advisory Service, designed to help foundations, philanthropists, and their advisors make more impactful investments in financing mechanisms medical research and better assess the return on philanthropy. to crowdsourcing of Previously, she worked in the health sciences practice of ideas, new players PricewaterhouseCoopers, advising commercial and federal are driving those clients across the healthcare continuum. Stevens received both her bachelor’s degree in biochemistry and master of business solutions forward. administration from Pennsylvania State University. —Melissa Stevens
Panel: Philanthropy: Investing for Impact In the Search for Cures
109 PANELISTS
SIMON STEVENS President, Global Health, UnitedHealth Group PARTNERING FOR CURES
I am optimistic because… Simon Stevens is president of the global health division at UnitedHealth Group, which serves 85 million people in 123 countries and manages $150 billion of healthcare annually. Interdisciplinary He also leads UnitedHealth’s work on U.S. health reform and innovation at the care innovation. Previously, Stevens was CEO of UnitedHealth’s interface of biology, $30 billion Medicare company and British Prime Minister Tony Blair’s Health Director at 10 Downing Street. He has also run engineering, and health systems on both sides of the Atlantic, as well as worked information sciences. in Africa and South America. He was educated at Oxford, Strathclyde, and Columbia universities, and was visiting —Simon Stevens professor at the London School of Economics. He is a director of the Commonwealth Fund, the Nuffield Trust, and the US- Brazil Business Council, among other current commitments.
Panel: Rare Diseases: Hot, but for How Long?
110 PANELISTS PARTNERING FOR CURES FOR PARTNERING HALLE TECCO Co-Founder and CEO, Rock Health
What’s standing in the way: Halle Tecco is the co-founder and CEO of Rock Health, a startup accelerator at the intersection of health and technology. Tecco is responsible for building partnerships Compared to other and overseeing Rock Health’s strategic direction. She previously industries that worked for Intel and Apple, and founded YogaBear.org. have gone through Tecco earned a bachelor of science degree at Case Western Reserve University and a master of business administration a technological degre from Harvard Business School where she worked revolution, demand on projects for Pandora, Nike, NASA, and Harvard Medical for healthcare is School. Tecco was named one of CNN’s “12 Entrepreneurs inelastic. People Reinventing Healthcare” and Forbes “30 under 30”. will always need healthcare—we need to find a way to meet those needs, for the entire population. —Halle Tecco
Panel: Five People Changing the Face of Bioscience
111 PANELISTS
MARC TESSIER-LAVIGNE President, The Rockefeller University PARTNERING FOR CURES
I am optimistic because… Marc Tessier-Lavigne is president of The Rockefeller University, where he is also Carson Family Professor and head of the Laboratory of Brain Development and Repair. He is a The past 20 years of pioneer in the study of the molecular signals that direct the scientific advances formation of neural circuits in the brain during embryonic have revolutionized our development. He also studies nerve cell responses to injury and the mechanisms underlying nerve cell death. Prior to ability to identify drug joining Rockefeller, he served as executive vice president for targets and patients research and chief scientific officer at Genentech and held who respond. We can faculty positions at the University of California, San Francisco conquer many diseases and Stanford University. A Rhodes Scholar, Tessier-Lavigne is the recipient of numerous awards and honors. He obtained provided we organize undergraduate degrees from McGill and Oxford universities and resource the R&D and a doctorate from University College London. enterprise adequately. —Marc Tessier-Lavigne
Panel: Big Science in the 21st Century
112 PANELISTS PARTNERING FOR CURES FOR PARTNERING JACK TILLMAN Executive Director, Emory Innovations, Emory University
I am optimistic because… Jack Tillman supports the leadership teams of Emory through multiple positions spanning programmatic and corporate domains in strategic development and implementation for I am optimistic about Emory University and its Robert W. Woodruff Health Sciences the future of medical Center. Tillman serves as senior advisor (and former interim R&D because I know president) for Saint Joseph’s Translational Research Institute, an operating company subsidiary of the newly formed Emory/ many people with Saint Joseph’s, Inc. and is leading the organization through diverse perspectives restructuring to refocus it on core activities in translational who easily agree on its testing and training. Tillman holds a founding leadership importance and impact role as executive director of Emory Innovations, Inc., a newly formed wholly owned holding company for the university on everyday lives, and engaged in innovative new business and corporate enterprises we just started. with a mission to support and enhance broader goals of Emory. —Jack Tillman
Panel: The New Value Proposition for Academic Science
113 PANELISTS
LUKE TIMMERMAN Vice President, Life Sciences Initiatives, Xconomy PARTNERING FOR CURES What’s standing in the way: Luke Timmerman is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the US biotechnology reporter for Bloomberg News, based in The challenge is San Francisco. There, he led coverage of major medical figuring out who will meetings and broke news about the industry’s top companies. continue to invest in His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, the long, risky journey his passionate coverage of biotechnology won many awards for of innovation, and The Seattle Times. He was also previously a Knight Science who will pay for these Journalism Fellow at MIT. Timmerman holds a bachelor’s degree products in the end. in journalism from the University of Wisconsin-Madison. — Luke Timmerman
Panel: Learning To Love Failure
114 PANELISTS PARTNERING FOR CURES FOR PARTNERING ADRIEN TREUILLE Assistant Professor, Computer Science and Robotics, Carnegie Mellon University
I am optimistic because… Adrien Treuille is an assistant professor of computer science and robotics at Carnegie Mellon University, working in the computer graphics group. He was one of the creators of Foldit, A 35-year-old librarian the computer game where users contribute to science by from Denmark discovered folding proteins. He also focuses his research efforts on the new RNA folding patterns simulation and animation of very high-dimensional nonlinear phenomena like animal morphology, human motion, and large by playing a scientific fluid systems. While his research seeks theoretical advances, computer game. he is also deeply interested in the implications for science and engineering of these techniques, from fluid dynamics —Adrien Treuille to laying down a joint cognitive and biomechanical basis for animal motion. Treuille received his doctorate in the computer graphics group at the University of Washington, and did his postdoctorate work at the Baker Group.
Panel: Five People Changing the Face of Bioscience
115 PANELISTS
STEPHEN J. UBL President and CEO, AdvaMed PARTNERING FOR CURES I am optimistic because… Stephen J. Ubl is president and CEO of AdvaMed, the world’s largest medical technology association. Ubl is recognized as a top healthcare advocate and policy expert across multiple Advanced medical health policy sectors, having successfully worked with devices and medical technology manufacturers, hospitals, patient groups, diagnostics allow physicians, and public and private payers. His lobbying accomplishments include passing landmark reforms related people to live longer, to the Food and Drug Administration product review process healthier, and more and Medicare’s coverage and reimbursement of medical productive lives while technologies. He joined AdvaMed in 1998 as executive vice yielding savings president of federal government relations, left the organization to open his own healthcare consulting firm, and returned to across healthcare AdvaMed to lead it in 2005. Previously, Ubl was vice president systems – ensuring of legislation for the Federation of American Hospitals and a good bargain for worked for U.S. Senator Charles E. Grassley. patients worldwide. —Stephen J. Ubl
Panel: Reimbursement: Can Value Drive Innovation?
116 PANELISTS PARTNERING FOR CURES FOR PARTNERING MARK WAGAR President, Heritage Medical Systems
Mark Wagar is president of Heritage Medical Systems, an affiliate of the Heritage Provider Network. Heritage was founded by Dr. Richard Merkin in 1979 and is the nation’s leading physician- Follow the money. led healthcare solutions organization. Previously president and Collaborate with CEO of Empire BlueCross BlueShield, Wagar led New York’s who pays the bills. largest health insurer covering nearly 6 million people, and was a senior vice president in WellPoint, Inc. Prior to Empire, Technologies and Wagar held leadership positions at Caremark, CIGNA products that improve HealthCare, and provider-owned managed care organizations, individual health as well as roles in hospital management, physician practice status, lower overall management, and diagnostic services in market-leading population health cost, organizations based in Ohio, California, Texas, and New York. rapidly replacing less effective approaches are winners. —Mark Wagar
Panel: The Other Translation Gap: Turning Outputs into Outcomes
117 PANELISTS
JOHN WALSH President and CEO, Alpha-1 Foundation PARTNERING FOR CURES
I am optimistic because… John W. Walsh was diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) in 1989. Learning there was no organized effort to promote research and find a cure for the disorder, he decided Our participation with to dedicate his life’s work to this end. In 1995 he co-founded FasterCures has created the Alpha-1 Foundation, a not-for-profit corporation dedicated an opportunity to connect to providing the leadership and resources to increase research, improve health, promote worldwide detection, and find a cure with organizations, for Alpha-1. Under his leadership, the organization has become individuals, and internationally recognized and has invested more than $28 million best practices that to support Alpha-1 research and research-related projects. have significantly Walsh has an extensive background in business management impacted our ability to and government relations. accelerate therapeutic development for Alpha-1 Antitrypsin deficiency. — John Walsh
Panel: The Other Translation Gap: Turning Outputs into Outcomes
118 PANELISTS PARTNERING FOR CURES FOR PARTNERING GEORGE A. WEISS Founder, Orphan Disease Pathway Project
George Weiss is the president of George Weiss Associates, Inc. and CEO of Weiss Multi-Strategy Advisers, LLC. George Weiss Associates, founded in 1978, has offices in Hartford, Conn. and New York. Weiss is the founder of the Orphan Disease Pathway Project, a nonprofit organization dedicated to finding cures and effective treatments for rare diseases. He is also the founder and chairman of Say Yes to Education, a nonprofit organization committed to dramatically increasing high school and college graduation rates for low-income students. At the University of Pennsylvania, Weiss is former vice chair of the board, immediate past chair of the development committee, and was chair of the Making History Campaign. He earned a bachelor’s degree from the University of Pennsylvania’s Wharton School of Finance.
Panel: Philanthropy: Investing for Impact In the Search for Cures
119 PANELISTS
PAUL WEISS Director, California NanoSystems Institute PARTNERING FOR CURES I am optimistic because… Paul S. Weiss is director of the California NanoSystems Institute, Fred Kavli Chair in NanoSystems Sciences, and distinguished professor of chemistry & biochemistry and of Because brain function materials science & engineering at UCLA. His research explores and malfunction take the ultimate limits of miniaturization. With his research group place at the nanoscale, and collaborators, he develops new nanoscale devices at ever smaller scales and greater chemical specificity in order to nanotechnology is connect to the biological and chemical worlds, including the uniquely poised to brain. He has published more than 300 papers and patents, make important has given more than 500 invited lectures, and is the founding contributions to editor of ACS Nano. neuroscience and the diagnosis and treatment of diseases of the brain. —Paul Weiss
Panel: Mental Health: Research and Development at a Crossroads
120 PANELISTS PARTNERING FOR CURES FOR PARTNERING CINDY WU Co-Founder, Microryza
Cindy Wu is a co-founder of Microryza. While she was a researcher at the University of Washington, Wu discovered a potential way to create an antibiotic to treat methicillin-resistant Staphylococcus aureus (MRSA). However, there was no way to get the small amount of funding she needed to run some initial tests. Luckily her professor funneled money from an existing National Institutes of Health grant to fund her side project. Inspired by this experience, in 2012 she and Denny Luan founded Microryza. Microryza is a U.S. Web site for crowdfunding science-based research projects where researchers can post their research projects to solicit donations. Wu received her bachelor of science in cellular, molecular, and developmental biology from the University of Washington.
Panel: The People Behind the Science: Will Work for Food
121 PANELISTS
RONI ZEIGER Co-Founder and CEO, Smart Patients PARTNERING FOR CURES
Roni Zeiger is the former chief health strategist at Google, where he led efforts ranging from Google Flu Trends to Symptom Search. In 2012, he and Gilles Frydman founded Smart Patients, a company that aims to amplify the knowledge created by networks of engaged patients. Zeiger serves as CEO of Smart Patients and continues to see patients part-time at a local urgent care center. He also advises several companies, including Medic Mobile, Qpid.me, ShareTheVisit, and Hobnob. Zeiger earned his medical degree at Stanford University and completed his internal medicine residency at the University of California, San Francisco. He has served as a clinical instructor of medicine at Stanford University School of Medicine and received a master’s degree in biomedical informatics from Stanford.
Panel: Big Data Needs Big Ideas
122 EXPERT CONSULTANTS Experts will provide pro bono issue analysis and tailored feedback based on participants’ specific needs and challenges, and will be available through the partnering system, P4C Connect.
STRATEGIC PLANNING CONSULTANTS EXPERT
These consultations will address strategic and business model issues, including establishing planning guidelines and timelines, conducting strategic analysis and organizational assessments, setting or changing strategic direction, refining goals and methods, approaching collaborations (with both partners and funders), and mapping/ CURES FOR PARTNERING measuring success.
RUSSELL L. BROMLEY Principal TRAC Consulting
In 2010, Russell L. “Rusty” Bromley formed TRAC Consulting to assist nonprofit medical research organizations in Translational Research Acceleration via Collaboration (TRAC). TRAC Consulting specializes in designing and implementing strategic research plans and collaborative operational models that are aligned with an organization’s mission and the unmet medical needs of patients. Prior to founding TRAC Consulting, he served for seven years as the chief operating officer of the Myelin Repair Foundation (MRF), where he was instrumental in the creation, implementation, and evolution of the MRF Accelerated Research Collaboration™ model. His principal responsibilities included development and execution of the MRF research plan, identification and protection of resulting intellectual property, and development of relationships with a broad range of academic and commercial organizations. Bromley brings a unique combination of business experience in both academic and commercial research environments. He has served as CEO of LabVelocity, Inc., an Internet information portal for the life science research community; CEO of Berkshire Holding Corporation, a privately held, multinational manufacturer of supplies for microelectronics and pharmaceutical production; and spent 17 years with American Hospital Supply Corporation and Baxter Healthcare. Bromley has a degree in biochemistry from Rice University.
125 STRATEGIC PLANNING
JOHN BURKLOW Associate Director for Communications and Public Liaison
EXPERT CONSULTANTS National Institutes of Health
John Burklow directs the National Institutes of Health (NIH) Office of Communications and Public Liaison and oversees media operations, online communication, editorial operations, major events, visitor and community programs, and other efforts. Burklow and his staff coordinate and integrate communication among NIH’s 27 institutes and centers, the U.S. Department of Health and Human Services, stakeholders, and public affairs offices at NIH’s worldwide grantee and contract institutions. Burklow serves as the chief advisor to senior agency leadership on communications issues and is also the agency chief spokesperson on non-science issues. He recently spearheaded an unprecedented overhaul of the $31 billion agency’s visual presence, including the development of strategic communications resources, PARTNERING FOR CURES a new logo and trademarked tagline, and other resources. Agency communications efforts have recently expanded into social media and the mainstream press, such as the Colbert Report and the NIH director’s presence at the World Economic Forum, the TEDMED set of conferences, and the 2012 Celebration of Science program, organized with FasterCures. Another novel collaboration is a trans-NIH working group dedicated to improved participation in clinical research. Burklow received the 2012 Presidential Rank Award, conferred by the president for exceptional service to the American people over an extended period of time.
ELAINE GALLIN Principal QE Philanthropic Advisors
Elaine K. Gallin is a partner at QE Philanthropic Advisors, a consulting firm that serves nonprofits specializing in biomedical research, science and math education, and international health, by helping them with strategic planning and program development. Previously, Gallin was the Doris Duke Charitable Foundation’s (DDCF) first program director for medical research. In that capacity, she developed and managed a grant portfolio that committed more than $185 million to support clinical investigators and speed the development of new therapies, cures, and preventions for human diseases. With Gallin’s leadership, DDCF also helped build the Doris Duke Medical Research Institute in Durban, South Africa, and launched a $65 million 2007 African Health Initiative to support large-scale health services delivery projects linked to rigorous operations research in several sub-Saharan African communities. She also worked for two decades as a research physiologist and an administrator for the U.S. government. Gallin has participated in numerous professional committees and currently serves on the board of the MedStar Health Research Institute, the Avon Foundation Scientific Advisory Board, and the President’s Council of Cornell Women. She is an adjunct associate professor in the department of microbiology and immunology at Georgetown University Medical School. 126 STRATEGIC PLANNING CONSULTANTS EXPERT
MOLLY MULDOON Principal GMM Health Strategies
Molly Muldoon is one of the principals of GMM Health Strategies, a professional CURES FOR PARTNERING consultancy specializing in the healthcare regulatory environment in Washington, and consultant to MyOwnMed, a medication adherence platform. Previously she served as the vice president of public policy for Onyx Pharmaceuticals, where she was responsible for establishing and leading key policy and regulatory positions for the company. Muldoon was formerly the Federal Drug Administration’s chief of staff, overseeing operations and liaising with senior leadership across the federal government on key issues including the Affordable Care Act, Deepwater Horizon, food safety regulations, and foodborne outbreaks. As a seasoned leader in organizational change and strategic planning, she has served as the chief administrative officer for both the National Restaurant Association and AARP Services. During her respective tenures she guided the organizations through organizational re-alignments and strategic planning efforts and assisted with identifying increased efficiency opportunities and expanding public outreach activities. Muldoon served in the Clinton Administration for both terms at the White House and the Department of Health and Human Services (HHS). Her roles included special assistant to the White House chief of staff, special assistant to counselor for the president, and special assistant to the deputy secretary of HHS.
DEAN ROSEN Partner Mehlman Vogel Castagnetti Inc.
A partner at Mehlman Vogel Castagnetti Inc., Dean Rosen provides policy counsel and strategic advice to policy makers, business leaders, trade association executives, and nonprofit organizations on a broad range of health issues. At Mehlman Vogel Castagnetti Inc., Rosen has represented major health systems, physician specialty organizations, private health plans, clinical laboratories, biotechnology companies, pharmaceutical manufacturers, and national employers seeking to comply with the Patient Protection and Affordable Care Act and affect national health policy. Prior to joining Mehlman Vogel Castagnetti Inc., Rosen held a series of high-level government and private sector positions. He was the chief healthcare advisor to Senate Majority Leader William H. Frist, MD. Previously, he was senior vice president of policy and general counsel for the Health Insurance Association of America (HIAA). He came to HIAA from a position as majority counsel for the House Ways and Means Health Subcommittee. He also served as health policy coordinator and majority counsel to the Senate Committee on Labor and Human Resources.
127 COLLABORATION STRUCTURING
These consultations will address various methods for formalizing and carrying out cross-sector partnerships as efficiently and effectively as possible. This category covers issues such as intellectual property, EXPERT CONSULTANTS data sharing, and conflicts of interest to ensure that the proper legal and structural agreements/policies/processes are in place for successful collaborations.
STEPHEN JOHNSON Chief Intellectual Property and Policy Officer PARTNERING FOR CURES OneMind4Research
Stephen Johnson has more than 30 years of experience in intellectual property law, beginning his career at Bird & Bird in London. He subsequently became an associate and partner with Kirkland & Ellis LLP in Chicago, and continued his career as a founding partner and head of the intellectual property groups of both Kirkland’s New York and San Francisco offices. Johnson’s legal practice focused on domestic and international intellectual property-based transactions, including joint ventures, product development, university collaborations, outsourcing, finance, royalty buyouts and securitization, and technology- driven corporate transactions. He worked predominantly on transactions in the life science and software industries and worked with senior management of clients on a wide range of legal issues including intellectual property risk management and strategy. Among other distinctions, Johnson was listed in Chambers USA: Leading Lawyers for Business and was named as one of America’s top 25 pre-eminent Information Technology practitioners in the publication Guide to the World’s Leading Lawyers - Best of the Best USA, 2011. He is a former chair of the Technology Committee of the International Bar Association. Johnson obtained a degree in natural sciences (genetics) from Cambridge University and graduated from law schools in London and Chicago.
128 COLLABORATION STRUCTURING CONSULTANTS EXPERT
STEWART LYMAN Owner and Manager Lyman Biopharma Consulting LLC
Stewart Lyman, Ph.D, has more than 35 years’ experience in research and biotechnology. CURES FOR PARTNERING In 2004, he started Lyman BioPharma Consulting LLC to share his expertise and advice on setting up and running successful collaborations with outside investigators. Lyman began his career in 1988 when he joined Immunex Corporation as a molecular biologist. Over the next decade he cloned a number of important human growth factors including flt3 ligand, which he helped lead into the clinic for stem cell mobilization and cancer immunotherapy trials. In 1998, Lyman was appointed the director of extramural research at Immunex, and in the next four years he ran the largest extramural research program in the United States. His group managed more than 2,500 research collaborations, shipping more than 1,000 distinct reagents to more than 1,000 academic and industrial groups at institutions worldwide. As director, he developed an innovative system for the timely collection, distribution, and storage of data from collaborators, and his emphasis on inspecting collaborators’ data for intellectual property opportunities significantly expanded Immunex’s patent portfolio. Lyman holds 25 U.S. patents and has authored or co-authored 129 scientific publications as well as numerous articles on collaboration management. He also reviews preclinical data for clients.
TERI MELESE Assistant Vice Chancellor Industry Research Alliances, University of California, San Diego
Before her current position, Teri Melese was a professor in the Department of Medicine at the University of California, San Francisco (UCSF) from 2001 to 2012 and held the position of director of business strategy and development for the School of Medicine. Working with institute and center directors, individual faculty, and life science companies, she crafted and implemented research collaborations. She also served on the Executive Leadership Team of the Helen Diller Family Comprehensive Cancer Center. Before joining UCSF in 2001, she ran an independent research laboratory in yeast genetics and molecular biology at Columbia University from 1988 to 1997, where she was awarded the prestigious National Science Foundation Young Presidential Investigator Award. In 1997 she left Columbia to be founding member of a venture-backed startup company, Iconix Biosciences (acquired by Entelos). She has four patents for biomedical technologies and small molecule inhibitors. Melese holds a bachelor of arts from the University of California, Berkeley, a doctorate in cell biology from UCSF (Regents Fellow), and was an American Cancer Senior Postdoctoral Fellow at the University of California, Los Angeles.
129 COLLABORATION STRUCTURING
KEN SCHANER Partner
EXPERT CONSULTANTS Schaner & Lubitz, PLLC
Ken Schaner is managing partner of Schaner & Lubitz, PLLC, where he has represented many for-profit and nonprofit entities in the corporate and tax aspects of a wide variety of agreements, transactions, financings, licenses, mergers, and acquisitions. Schaner serves as general and outside counsel to many nonprofits and has represented the Cystic Fibrosis Foundation, JDRF, Stanley Medical Research Institute, National Neurovision Research Institute, National Multiple Sclerosis Society, and others in numerous venture philanthropy transactions and related legal matters. Schaner began his career at the Internal Revenue Service’s legislative and regulations division. He holds a bachelor’s degree and J.D. from the
PARTNERING FOR CURES University of Illinois.
EUGENE WILLIAMS CEO DART Therapeutics
Eugene Williams is the CEO of DART Therapeutics, a biotech founded by patient foundations in Duchenne muscular dystrophy. He is a former senior vice president at Genzyme, with senior roles in commercialization, drug development, and deal making. He is also an entrepreneur, as the founder and director of Adheris, which became the largest company in the patient adherence area. He was previously a strategy consultant at Bain and CDI (now part of Oliver Wyman), where he spent extensive time on speeding and improving the drug development process and on commercialization strategies. His areas of experience include the evolving role of patient foundations, creative structures for dealmaking, effective collaboration and alliance management, innovative models for rare diseases and new approaches and roles for patient groups in commercialization, drug development strategies, portfolio management, drug development efficiency, and innovative business models. He has a bachelor’s degree in economics from Harvard College and a master of business administration from Harvard Business School.
130 ATTRACTING CAPITAL CONSULTANTS EXPERT
These consultations will focus on funding. Consultants will come from both the foundation and investor perspectives and will provide best practices and guidance around the strategic acquisition and allocation of capital (i.e., evaluating philanthropic investment, building a high-impact medical portfolio, attracting investors, resource-building, etc.). CURES FOR PARTNERING
CHRISTOPHER EARL President Innotrove LLC
Christopher D. Earl is an entrepreneur, investor, and nonprofit leader with broad experience in science, venture capital, and the management of biotechnology companies and nonprofit organizations. He serves as senior advisor to the Merck Global Health Innovation venture capital fund, and through Innotrove LLC advises other leading biopharma companies. Previously, Earl was the first president and CEO of BIO Ventures for Global Health (BVGH), a nonprofit organization devoted to harnessing biotech R&D to develop cures for neglected tropical diseases. Supported by industry and the Bill & Melinda Gates Foundation, BVGH promoted financial incentives for tropical disease R&D and forged collaborations between leading companies and research institutions. Earl joined Perseus Capital in 1997 to build its investment portfolio in biotechnology and launched the Perseus-Soros BioPharmaceutical Fund. He led investments in companies developing therapeutics for oncology and infectious diseases, and served as a director on portfolio company boards. Several of these companies achieved Food and Drug Administration approval for innovative drugs that today sell more than $1 billion. Earl serves on the boards of Daktari Diagnostics, Asuragen, and Mirna Therapeutics. He is a trustee of the Nature Conservancy of Maryland/DC. Earl received his doctorate in cellular and developmental biology from Harvard University.
131 ATTRACTING CAPITAL
DENNIS FORD CEO
EXPERT CONSULTANTS Life Science Nation
Dennis Ford is an entrepreneur, author, and thought leader who is an expert in sales, marketing, and business development. He has spent most of his career launching new companies and developing a market for nascent game-changing technologies. Ford has distinct value in understanding the world of global alternative investors and how that relates to high-growth early-stage technologies. His expertise encompasses using database subscription services to create business solutions and using the Internet to create an interactive dialogue between buyers and sellers. Ford is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling
PARTNERING FOR CURES process. He is the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books. Prior to joining Life Science Nation, Ford was the CEO of Brighton House Associates (BHA), which was launched in order to improve the way hedge fund and private equity fund managers raised capital and marketed their funds to investors. As CEO, he introduced a marketing process that was investor-focused and expanded BHA’s reach, attracting clients in the Americas, Europe, the Middle East, and Asia, and investors in more than 200 countries.
ERIN HOGAN Executive Director The Philanthropy Centre at J.P. Morgan
Erin Hogan, vice president, serves as a senior philanthropic advisor for individuals, families, private foundations, and charitable trust clients of J.P. Morgan Private Bank. Hogan specializes in giving programs in the areas of health, international relief, k-12 and higher education, and social services. Before joining J.P. Morgan, Hogan was a research manager at Columbia University’s Mailman School of Public Health, where she supervised research programs in emergency preparedness, infectious disease control, and occupational health and safety. Prior to that, Hogan worked for a Washington consulting firm on a variety of public health and environmental safety projects for government agencies such as the U.S. Environmental Protection Agency and the Federal Emergency Management Agency. Hogan is a former paramedic and has volunteered with the American Red Cross and organizations serving individuals with HIV/AIDS. She currently serves on the alumni board for the Mailman School of Public Health at Columbia University and the Partnerships Committee for the Global Alliance for Vaccines and Immunization. She also is a member of Grantmakers in Health and Grantmakers for Education. Hogan has a master of public health degree from Columbia University and a bachelor of science in health sciences from The George Washington University. 132 CLINICAL RESEARCH, REGULATORY, CONSULTANTS EXPERT & REIMBURSEMENT STRATEGY
These consultations will address strategies for effectively managing protocol development, study site selection, subject recruitment, project management, patient controls, and site monitoring. CURES FOR PARTNERING They may also touch on regulatory, reimbursement, and marketing concerns related to trial development, and the role and future of virtual populations.
CHRIS BOONE Vice-President Evidence Translation & Implementation, Avalere Health
Chris Boone advises clients on value strategies, market access, and evidence generation. He works with life sciences companies, healthcare providers, professional societies, and patient advocacy groups to conduct quality improvement and comparative effectiveness research using electronic clinical data. Boone’s relevant experience includes strategy, organizational redesign, and operational effectiveness projects. Prior to joining Avalere, he was the national director of outpatient quality and health IT for the American Heart Association. Boone has a bachelor of science degree in management information systems from the University of Tulsa, a master of health administration degree from the University of Texas at Arlington, and a doctorate from the University of Texas at Dallas. Most recently, he was a sitting member on the Office of the National Coordinator’s Health IT Policy Committee and co-chair for the National Council on Heart Disease Technology at the eHealth Initiative. Boone sits on the Advisory Group for American Society of Clinical Oncology’s CancerLinQ initiative. He is also a fellow of the American College of Healthcare Executives.
133 CLINICAL RESEARCH, REGULATORY, & REIMBURSEMENT STRATEGY
EXPERT CONSULTANTS JUDITH KRAMER Senior Scientific Advisor Clinical Trials Transformation Initiative
Judith Kramer is the senior scientific advisor for the Clinical Trials Transformation Initiative (CTTI). She oversees all activities and operations of the partnership under the direction of the chair and co-chair, Dr. Robert M. Califf, vice chancellor for clinical research at Duke University, and Dr. Rachel Behrman, director of the Food and Drug Administration’s Office of Critical Path Programs. The goal of CTTI is to improve and modernize the operational
PARTNERING FOR CURES performance of the clinical research enterprise by convening experts in the field and undertaking projects to identify existing issues related to current practice, design models for improvement, test the new procedures and compare them to previously existing systems, and develop recommendations to inform policymakers. Prior to her current position, Kramer worked for 10 years at Burroughs Wellcome Co., where she was vice-president and director of U.S. Clinical Research. Kramer was also the chief medical officer at DCRI, where she provided guidance and consultation on the formation of the regulatory affairs and quality assurance functions at DCRI. Kramer has a bachelor of science and master of science in clinical pharmacy and is board-certified in general internal medicine, having practiced internal medicine in the community for five years.
LINDA A. MALEK Partner Moses & Singer LLP
Linda A. Malek is a partner at Moses & Singer and chair of the firm’s Healthcare and Privacy and Cybersecurity departments. Malek counsels healthcare organizations and financial institutions on transactional matters in the healthcare industry, including mergers and acquisitions, healthcare privacy issues, risk arrangements involving large health maintenance organizations, and contractual issues relevant to academic medical centers concerning human subject research. She also represents and counsels academic medical centers, biotechnology companies, pharmaceutical companies, biorepositories, scientific research consortia, and research foundations. Committed to advancing the quality of healthcare in the United States through innovations in information technology, Malek has been appointed by the Markle Foundation to their Health Information Exchange Advisory Committee, part of the “Markle Connecting for Health” public-private collaboration to enable secure and private information sharing. Prior to joining Moses & Singer, Malek spent nearly six years as a healthcare attorney for the Office of the Corporation Counsel, Division of Legal Counsel, where she was named Outstanding Assistant Corporation Counsel by the Association of the Bar of the City of New York. She holds a bachelor of arts from Walla Walla College and a law degree from the University of Virginia School of Law. 134 CLINICAL RESEARCH, REGULATORY, CONSULTANTS EXPERT & REIMBURSEMENT STRATEGY
BRAY PATRICK-LAKE
Director of Stakeholder Engagement CURES FOR PARTNERING Clinical Trials Transformation Initiative
Bray Patrick-Lake supports efforts to actively engage patient advocacy organizations and other stakeholders in Clinical Trials Transformation Initiative (CTTI) efforts to improve clinical trials. She also implements strategies to enhance awareness of CTTI’s work, particularly with patient advocates, and to extend the impact of CTTI results and recommendations. During the past 15 years, Patrick-Lake has founded and led several nonprofit organizations, including the PFO Research Foundation, which she started in response to the lack of definitive scientific information regarding the condition of patent foramen ovale (PFO). Patrick-Lake has served as a patient representative at the Food and Drug Administration on a variety of advisory committees and panels, in workgroups for the European Medicines Agency and the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, as a guest lecturer and an external reviewer for the Institute of Medicine, and as a key stakeholder for Agency for Healthcare Research & Quality and Patient-Centered Outcomes Research Institute grants. She is a board member for the Alliance for Headache Disorders Advocacy. She holds a bachelor of science in zoology from the University of Georgia and a master of forensic sciences degree from National University.
CYNTHIA RICE Senior Vice President of Advocacy and Policy JDRF
Cynthia Rice is responsible for JDRF’s advocacy to Congress, the executive branch, regulatory agencies, and health plans to accelerate therapies to cure, treat, and prevent type 1 diabetes. She joined JDRF, then known as the Juvenile Diabetes Research Foundation, in 2005 and led a cross-departmental staff team that developed the Artificial Pancreas Project. Rice has extensive experience leading complex advocacy projects in both the government and nonprofit sectors. In the White House from 1997 to 2000, she served as a special assistant to the president for domestic policy, coordinating numerous high-profile policy initiatives involving experts from multiple agencies. Prior to joining the White House, she served in the U.S. Senate as a legislative assistant to two senior members of the Finance Committee, Senator Daniel Patrick Moynihan and Senator John B. Breaux. In those capacities she helped advance and amend a variety of budget, health, and domestic policy legislation. From 2001 to 2005, Rice served as vice president for policy at the New Democrat Network, where she led efforts to promote the group’s policy agenda to elected officials and the public. Rice has a master of public policy from the University of California, Berkeley, and a bachelor’s degree from Harvard University.
135 CLINICAL RESEARCH, REGULATORY, & REIMBURSEMENT STRATEGY
EXPERT CONSULTANTS ALICIA SABLE-HUNT President & Founder Edwards-Hunt Group LLC
Alicia Sable-Hunt has invested more than 18 years working in the fields of nursing and clinical research, specializing in oncology and transplant patient populations. After years of bedside nursing, she transitioned to the management of oncology clinical trials for healthcare institutions. Hunt’s formal background and experience enabled her to develop the clinical operations of a disease-specific nonprofit, including an oncology clinical trials
PARTNERING FOR CURES program and disease-specific biorepository. She works from the premise that biobanking is the foundation for precision medicine. In an effort to see this model become reality, Hunt founded a life science consulting firm to fully support nonprofit organizations developing translational medicine programs in order to drive drug development in the direction of their particular disease. Her firm expanded to include a biospecimen acquisition network offering the biopharmaceutical and diagnostic industries prospective collection of human tissues and supporting clinical research services. Through her expansive network, Hunt facilitates the collection, storage, and distribution of high-quality, annotated biospecimens collected under U.S. regulatory standards to accommodate research applications used in the drug discovery and device development process.
J. RUSSELL TEAGARDEN Senior Vice President Medical & Scientific Affairs, National Organization for Rare Disorders
At the National Organization for Rare Disorders (NORD), J. Russell Teagarden is responsible for the medical and scientific dimensions of research, programming, strategic alliances, and policy initiatives, among others. He joined NORD after 19 years at Medco Health Solutions, where he was chiefly involved in drug technology assessment, coverage policy, clinical programming, research, and clinical oversight. Prior to joining Medco, he practiced as a clinical pharmacist in critical care and drug information in the Chicago teaching hospital community. Teagarden has a bachelor of science in pharmacy, a master of arts in research methods, and a doctorate in medical humanities. He completed a residency in hospital pharmacy at Northwestern University Medical Center and was a visiting scholar at the National Institutes of Health Bioethics Department.
136 DATA NETWORKING CONSULTANTS EXPERT
These consultations will address strategies for designing, implementing and managing your own data networks (including sharing information across networks and sectors), and/or for utilizing information captured in existing networks for clinical research purposes. CURES FOR PARTNERING
AARON ABEND Advisory Board Member Northwest EHR Collaborative
Aaron Abend has been a leader in data warehousing technology for more than 20 years. After stints in Washington and Wall Street, he entered the field of data warehousing when he joined Metaphor Computer Systems in 1984 and worked with Ralph Kimball on one of the earliest data warehouse solutions. He launched Abend Associates, Inc., in 1985 and consulted to customers such as Chemical Bank, TIAA/CREF, and Procter & Gamble. In 1999, Abend entered the field of healthcare, working with Dr. Shawn Murphy on the Research Patient Data Registry project at Massachusetts General Hospital, which became the prototype for the National Institutes of Health-sponsored i2b2 system. In 2006, Abend cofounded Recombinant Data and helped implement i2b2 and data warehouse technology at hospitals and academic medical centers to improve the quality of care and research new treatments. Recombinant Data was acquired by Deloitte in 2012, and Abend worked as a director there until 2013. Since leaving Deloitte, Abend has been advising the nonprofit Northwest EHR on the implementation of a health information exchange in Montana and UV Therapeutics, a biotech startup. Abend earned a bachelor of arts at Middlebury College and a master of business administration from Columbia University.
137 DATA NETWORKING
SUE DUBMAN Bioinformatics Specialist and Patient Advocate
EXPERT CONSULTANTS Sue Dubman has more than 20 years of experience in bioinformatics and has led many innovative developments in clinical and translational research. Considered a thought leader in informatics, Dubman and her teams have received many awards and honors, including the National Cancer Institute’s (NCI) Scientific Achievement Award, the Service to America Medal in Science, Computerworld Honors in Science, the InfoWorld 100 Award, and the CIO-100 Award for innovation. Currently senior director, Sanofi R&D, she is spearheading global implementation of data standards and acting as a change agent focused on the development of new data management services as well as global information management governance. Prior to Sanofi, Dubman served as director of applications initiatives at NCI and vice president and chief information officer at two biopharma companies. At NCI, PARTNERING FOR CURES she was part of the original team that formed caBIG, one of the largest experiments in global data sharing. Dubman volunteers her time to support programs aimed at improving delivery of healthcare and research, including a long-standing working relationship with the University of California, San Francisco Breast Cancer Center of Excellence and as a Parkinson’s advocate. She did her graduate work at Brown and her undergraduate work at University of Missouri.
BRENT GENDLEMAN President and CEO 5AM Solutions
With 15 years of experience serving customers by listening to and articulating their needs in the software development industry, including the last 10 serving the biomedical community, Brent Gendleman has focused on providing a range of services that enable secure, Web- based collaboration across a global network of users and systems. Prior to forming 5AM Solutions, Gendleman was a practice manager for Number Six Software, where he built and led a software development team that produced 6-10 production-quality Web systems each year. He served life science clients such as the National Cancer Institute, the Hospital for Special Surgery, and the Children’s National Medical Center, in addition to significant contracts with the U.S. Air Force and the Bureau of Labor Statistics. Prior to Number Six, he spent two years performing international aid work in Germany and Yugoslavia, was a consultant with a subsidiary of SRA developing Web solutions for the Environmental Protection Agency, and holds five years of publishing experience at the standard for weekly scientific publishing, Science Magazine. Gendleman earned a bachelor of science from Syracuse University in television, radio, and film writing and a Web development certificate from George Washington University.
138 DATA NETWORKING CONSULTANTS EXPERT
KRIS JOSHI Vice President Global Health Sciences, Oracle
Kris Joshi is global vice president responsible for Oracle’s healthcare product portfolio. CURES FOR PARTNERING He helped launch the Health Sciences Global Business Unit within Oracle and led the business unit’s growth strategy, including the acquisitions of Relsys and Phase Forward. Joshi oversees a product portfolio that covers analytics, health information exchange, care management, and solutions for personalized medicine and translational research serving healthcare payer, provider, and life sciences segments. Prior to Oracle, Joshi served in senior strategy roles in IBM’s Global Sales & Distribution organization, where he helped shape IBM’s global distribution strategy and emerging markets strategy. Prior to IBM, he spent several years as a consultant with McKinsey and Co., where he served Fortune 500 clients in banking, media, healthcare, and life sciences industries on business strategy issues. Joshi has a long-standing personal commitment to help bridge the gap between the social and business worlds through entrepreneurship, innovation, and public-private partnerships. He has championed numerous initiatives aimed at leveraging technology to improve the quality, safety, and affordability of healthcare globally. Joshi holds a bachelor of science in mathematics from CalTech and a doctorate in astrophysics from MIT.
139
SPONSORS SPONSORS SPONSORS BENEFACTOR PARTNERING FOR CURES
LEADERSHIP CIRCLE
THE LEONAPLATINUM M. AND HARRY B. HELMSLEY CHARITABLE TRUST
GOLD
SILVER
BRONZE
142 SPONSORS SPONSORS PARTNERING FOR CURES FOR PARTNERING
“Groundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundation’s approach and help us speed scientific advances with potential to improve the treatment of Parkinson’s for patients today and in the future.”
–Todd Sherer CEO of The Michael J. Fox Foundation for Parkinson’s Research sanofi.com
143 SPONSORS SPONSORS PARTNERING FOR CURES
THE LEONA M. AND HARRY B. HELMSLEYEven as a relatively large foundation with significant resources,CHARITABLE we at the HelmsleyTRUST Charitable Trust recognize that no single organization can tackle life-threatening diseases on its own. Close collaboration with partners across the research, clinical, regulatory, and industry landscapes is essential to developing new devices and therapies and, hopefully one day, cures. We are particularly committed to aligning our grantmaking efforts with partners in private industry who are responsible for moving breakthrough treatments from the lab to the patients who need them.
helmsleytrust.org
144 When research evolves, cures evolve.
Great things happen when you bring together and support those on the front lines of moving science to market fueled by collaborations. This approach is necessary to accelerate the development of new therapies and bring those health care solutions to market. The Kauffman Foundation is committed to advancing medical innovations by helping to expand health care entrepreneurship.
That’s why we are proud to support the Institute for Advancing Medical Innovation at the University of Kansas and Partnering for Cures 2013.
www.kauffman.org @kauffmanfdn epefoundation.org COMBINING OUR STRENGTHS SHARING OUR SUCCESSES
YOU’VE DISCOVERED SOMETHING SIGNIFICANT...
NORTHWEST UNITED STATES SOUTHEAST UNITED STATES SOUTHWEST UNITED STATES
Steven Bartz, PhD Sanjeev Munshi, PhD, MBA James Schaeffer, PhD Director, External Scientific Affairs Director, External Scientific Affairs Executive Director, External Scientific Affairs Worldwide Licensing & Acquisitions Worldwide Licensing & Acquisitions Worldwide Licensing & Acquisitions Merck Research Laboratories Merck Research Laboratories Merck Research Laboratories 901 South California Ave 104 Ironwoods Drive 7825 Fay Avenue, Suite 320 Palo Alto, CA, USA 94304 Chapel Hill, NC, USA 27516 La Jolla, CA, USA 92037 Email: [email protected] Email: [email protected] Email: [email protected] Phone: +1 415 694 1373 Phone: +1 267 663 8898 Phone: +1 858 454 6502 ext. 102
NEW ENGLAND MID-ATLANTIC AND CANADA AND LATIN AMERICA MIDWEST UNITED STATES
Reid J. Leonard, PhD Susan Rohrer, PhD Steven Xanthoudakis, PhD Executive Director, External Scientific Affairs Executive Director, External Scientific Affairs Director, External Scientific Affairs Managing Director, Merck Ventures Fund Worldwide Licensing & Acquisitions Worldwide Licensing & Acquisitions Worldwide Licensing & Acquisitions Merck Research Laboratories Merck Research Laboratories Merck Research Laboratories PO Box 2000 9-2-446A, Research Building 9 33 Avenue Louis Pasteur, BMB 2–422A Rahway, NJ, USA 07065 16711 Trans Canada Highway Boston, MA, USA 02115 Email: [email protected] Kirkland, Quebec Email: [email protected] Phone: +1 732 594 7499 H9H 3L1, Canada Phone: +1 617 992 2321 Email: [email protected] Phone: +1 514 428 3461 NOW DISCOVER US! Contact one of our Regional Scientific Experts Merck seeks partnerships across many therapeutic areas and technologies. Learn more at www.merck.com/licensing
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved. Merck is known as MSD outside the United States and Canada. Pfizer is proud to support: FasterCures and the Partnering for Cures Conference
“Disease foundations provide a critical patient perspective and encourage a crisp focus on translating basic science into urgent clinical applications for patients in need. When foundations and industry partner together, it can have an amplifying and accelerating effect – optimizing the assets and capabilities of the industry partner and making it possible to pursue more research avenues, or de-risk the earlier stage research that is foundational for true medical breakthroughs.”
Mikael Dolsten, M.D., Ph.D. - President, Pfizer Worldwide Research & Development Forbes.com, December 7, 2012 SPONSORS SPONSORS PARTNERING FOR CURES FOR PARTNERING
Collaboration = Innovation
BIO believes in the power of partnerships. At BIO, we aim to facilitate collaboration between all stakeholders in the healthcare enterprise to spur and accelerate the development of innovative, cutting-edge therapies. Together, we can learn from one another, amplify our voices, and exchange ideas to fuel the discovery of tomorrow’s cures. BIO shares this vision with our partners at FasterCures and is proud to support Partnering for Cures 2013. www.bio.org
149
gene.com goldmansachs.com SPONSORS SPONSORS PARTNERING FOR CURES
Identifying, shaping, and on-boarding the most promising science and technology opportunities at universities, academic centers and small biotech companies with the goals of catalyzing early-stage innovation and bringing transformative medical solutions to patients faster.
jnj.com
154
SPONSORS SPONSORS PARTNERING FOR CURES
It takes many different partners to make medical progress a reality. Collaboration between the biopharmaceutical industry, academia, patient advocacy groups, and other stakeholders in the research ecosystem enables us to advance the shared goals of preventing diseases, improving health, and saving lives.
By working side by side on cutting-edge science, tools, and resources, collaborations allow us to maximize resources and pursue opportunities in fields such as personalized medicine and the growing understanding of rare diseases.
phrma.org
156 SPONSORS SPONSORS PARTNERING FOR CURES FOR PARTNERING
According to the World Health Organization, cancer- related deaths average about 7.5 million a year. In studies conducted by the American Cancer Society, cancer accounts for nearly one out of every four deaths in the United States alone.
Instituted in December 2010 and based in Switzerland, Rising Tide Foundation is dedicated to supporting promising, innovative clinical cancer and scientific studies to further accelerate research that provides hopeful, encouraging, and immediate options for cancer patients.
We are proud to support Partnering for Cures 2013, an outcomes-oriented and patient-focused event. risingtide-foundation.org
157 SPONSORS SPONSORS PARTNERING FOR CURES
Collaboration is the future of healthcare. Getting better treatments to market, faster and more cost-effectively, requires breaking down silos, collaborating across disciplines, and converging services as never before. inVentiv Health is committed to the seamless convergence of clinical and commercial expertise from around the world to help life science companies quickly get treatments to the people who need them.
That’s what we mean when we say inVentiv Health “transforms promising ideas into commercial reality.”
inventivhealth.com
158
MILKEN INSTITUTE STRATEGIC PARTNERS SPONSORS PARTNERING FOR CURES FOR PARTNERING
Sumner M. Redstone charitable foundation
161 LOS ANGELES APRIL 27-30, 2014
WE’LL SEE YOU IN 2014 TEAM TEAM TEAM
India Allenby Dale Bonner Ross C. DeVol Executive Assistant Senior Advisor; Chairman Chief Research Officer Plenary Group USA Martha Amram Christopher Diaz Senior Fellow; CEO Julianne Brands Accounting Supervisor WattzOn Program Assistant Richard Ditizio Sarah Anderegg LaTese Briggs Executive Director, Special Assistant to the Program Analyst Business and Program PARTNERING FOR CURES Director of Programs FasterCures Development and Communications Laura Brockway-Lunardi Jackson Dragon Margaret Anderson Scientific Program Director Senior Manager Executive Director Melanoma Research Alliance Operations and Administration FasterCures Chris Brummer Alain Dudoit Tracy Andreen Senior Fellow; Professor of Law Senior Advisor Receptionist/Administrative Georgetown University Law Ambassador of Canada (ret.) Assistant Center Dianna Dunne Or Arad Fran Campione Director Chief Operating Officer Executive Assistant Government Affairs Israel Center Alexandra Carney Jennifer Engel Cecilia Arradaza Scientific Program Manager Development Manager Director, Communications and Melanoma Research Alliance Melanoma Research Alliance Policy Ilyona Carter William H. Frey FasterCures Executive and Operations Senior Fellow; Research Professor, Jason Barrett Manager Population Studies Center Public Policy Analyst Melanoma Research Alliance University of Michigan James R. Barth Chan Heng Wing Jane Gachucha Senior Fellow Chairman Senior Accountant Asia Center Melissa Bauman Jie Gan Editor Anusuya Chatterjee Adjunct Fellow; Associate Senior Economist Professor of Finance Armen Bedroussian Hong Kong University of Senior Economist Robert Cook-Deegan Science and Technology Senior Fellow Michael Bernick FasterCures Ashley Gerson Adjunct Fellow; Special Counsel Event Coordinator to Sedgwick LLP; former Cathy Crear Director, California Employment Executive Assistant Daniel Gorfine Development Department Director Taylor Cronin Financial Markets Policy, Jared Bernstein Intern, FasterCures and Legal Counsel Senior Fellow; Senior Fellow, Robert Deuson Center on Budget and Policy Julia Guren Senior Managing Economist Priorities; former Chief Associate Health Economics Economist and Economic Adviser Business and Program to Vice President Joe Biden Development 164 TEAM TEAM PARTNERING FOR CURES FOR PARTNERING Priscilla Hamilton Lauren C. Leiman Julee McCarthy Research Analyst Director, Marketing and Executive Assistant Development Kathi E. Hanna K. Kimberly McCleary Melanoma Research Alliance Senior Fellow Director, Strategic Initiatives FasterCures Ross Levine FasterCures Senior Fellow; Willis H. Booth Kamyab Hashemi-Nejad Joe Meehan Chair in Banking and Finance Director of Finance Director University of California, Berkeley Database Management Paul H. Irving Tong (Cindy) Li President Michael Milken Adjunct Fellow; Chairman Ann Kahraman Country Manager Associate Federal Reserve Bank Clinton Misamore Database Management of San Francisco Associate, Business and Program Zachary Karabell Mark Lim Development Senior Fellow; President Innovation Program Manager River Twice Research FasterCures Jeff Monford Communications Consultant Kristen Keough Stephen Lin Research Analyst Research Analyst Orly Movshovitz-Landskroner Coordinator, Milken Institute Conrad Kiechel Susanna Ling Fellows Program, Israel Center Director of Communications Associate Director of Development Bernard Munos Jaque King FasterCures Senior Fellow, FasterCures; Research Analyst Founder, InnoThink Courtney Lyman Kevin Klowden Associate Kevin M. Murphy Director,California Center; Database Management Senior Fellow; George J. Stigler Managing Economist Distinguished Service Professor Caitlin MacLean Michael L. Klowden of Economics, University of Associate Director Chief Executive Officer Chicago Graduate School Financial Innovations Labs of Business Sindhu Kubendran Shantika Maharaj Research/Health Analyst Katie O’Reilly Executive Assistant to the Director, Vikrham Kumar CEO and the President Business and Program Intern, FasterCures Donald Markwardt Development Joel Kurtzman Research Analyst Joseph Ortega Senior Fellow; Marissa Maybee Operations Assistant Executive Director, Senior Communications and Outreach FasterCures Fellows Program; Manager Publisher, The Milken Institute Nancy Ozeas Melanoma Research Alliance Review Director, Programs Samantha Mayberry Laura Deal Lacey Gillian Parrish Program Assistant Managing Director Manager, Outreach and FasterCures Asia Center Communications FasterCures 165 TEAM TEAM
Peter Passell Sean Sandbach Jonathan Simons Editor, Senior Associate, Senior Fellow; The Milken Institute Review; Business and Program President and CEO Senior Fellow Development Prostate Cancer Foundation Lior Pe’er Sarah Sandler Frank Song Executive Assistant Associate Director, Adjunct Fellow; Israel Center Business and Program Founding Director,
PARTNERING FOR CURES Development Centre for China Louise M. Perkins Financial Research Chief Science Officer Richard L. Sandor University of Hong Kong Melanoma Research Alliance Senior Fellow; Chairman and CEO, Howard Soule Tomas J. Philipson Environmental Financial Senior Fellow; Executive Vice Senior Fellow; Daniel Levin Products LLC; Lecturer in President and Chief Science Professor of Public Policy Law and Economics Officer, Prostate Cancer Studies, Irving B. Harris University of Chicago Foundation Graduate School of Public Policy Studies Moutusi Sau Komal Sri-Kumar University of Chicago Program Research Analyst Senior Fellow; President Triphon Phumiwasana Keith Savard Sri-Kumar Global Strategies Adjunct Fellow; Senior Managing Economist Director of External Fund Melissa Stevens John Schellhase Management Deputy Executive Director Program Research Analyst Thai Government Pension Fund FasterCures Kristin Schneeman Apanard (Penny) Prabha Karlee Stewart Program Director Economist Communications Coordinator FasterCures FasterCures Bryan Quinan Mishi Schueller Director, Events Shawn Sullivan Email Marketing Associate and Program Associate Minoli Ratnatunga Project Coordinator FasterCures Economist Wendy K.D. Selig Phillip L. Swagel David Rice President and CEO Senior Fellow; Professor Africa Advisor Melanoma Research Alliance University of Maryland School Skip Rimer Edward Silver of Public Policy Executive Director, Editor Timothy Swope Programs and Communications Mindy Silverstein Research Policy Analyst Karen Rogers Managing Director FasterCures Communications Manager Lisa Simms Erin Tanenbaum FasterCures External Affairs and Operations Associate Director Sofia A. Sami Director Business and Program Program Associate FasterCures Development
166 TEAM TEAM PARTNERING FOR CURES FOR PARTNERING Robert H. Topel Ronnie Wiessbrod Elena Zager Senior Fellow; Brown Associate, Business and Senior Associate, Distinguished Service Program Development Business and Program Professor of Economics Development John Wilbanks University of Chicago Booth Senior Fellow, FasterCures; Steven Zecher School of Business Chief Commons Officer, Head, Regional Development Andrew C. von Eschenbach Sage Bionetworks and Project Finance, Senior Fellow; President, Israel Center Nevada Wolf Samaritan Health Associate, Database Betsy Zeidman Initiatives Inc.; former Management Adjunct Fellow; Executive Commissioner, Food Fellow, Center for Communication and Drug Administration; Perry Wong Technology Management, former Director, Director of Research University of Southern California National Cancer Institute Henry Woodside Allen Zhang Staci Warden Database Manager, Accounting Manager Executive Director Melanoma Research Alliance Center for Financial Markets Nan Zhang Glenn Yago Senior Research Analyst Teresa Whang Senior Director, Israel Center; Associate, Database Senior Fellow; and Founder, Maya Zuckerman Management Financial Innovations Labs Coordinator, Communications, Publications and Production Heather Wickramarachi Melody Yuan Israel Center Senior Research Analyst Social Media Coordinator
ACKNOWLEDGMENTS
We thank the following organizations for their support of Partnering for Cures:
Milken Family Foundation Execpro Services Jujama Inc Creative Services Information Services Partnering Database Services Event Production Technical Support Technical Support
167 The P4C Lounge Awaits Take a break from partnering and panels. Stop by the P4C Lounge, located on the Conference Level, to kick back, catch up with new and existing colleagues, and…
BE PART OF “THE BIG PICTURE.” Meet graphic recorder Tom Benthin who can transform your statement into a work of art.
POP INTO THE P4C PHOTO BOOTH. Create a memento that captures the energy of this meeting. Bring your game face, grab a prop or two, and strike a pose for cures. WHO WE ARE FasterCures, a center of the Milken Institute, is an action tank, determined to remove barriers to medical progress. We work to improve the medical research system—so that we can speed up the time it takes to get important new medicines from discovery to patients. WHAT WE DO At FasterCures, we work to clear the path to faster progress by educating stakeholders about the barriers, amplifying solutions, and creating opportunities for key leaders to come together and get things done. We work alongside patient advocates, researchers, investors, and policymakers across all sectors of the medical research and development system to achieve the following strategic goals through our programs.
• STIMULATE INNOVATIVE COLLABORATIONS across all sectors—academia, government, industry, investors, CONNECT WITH US and nonprofits. • INCREASE PATIENT ENGAGEMENT in research and optimize use of patient data. • IMPROVE RESEARCH PROCESS AND POLICY to support efficient development and approval of new therapies. • FACILITATE GREATER ACCESS TO AND MORE STRATEGIC ALLOCATION OF CAPITAL to support results-driven medical research. www. .org 1250 Fourth Street 1101 New York Avenue NW, Suite 620 Santa Monica, CA 90401 Washington, DC 20005 Phone: (310) 570-4600 Phone: (202) 336-8900
E-mail: [email protected] E-mail: [email protected] www.milkeninstitute.org www.fastercures.org